| Year |
Citation |
Score |
| 2024 |
Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, ... DeMichele AM, et al. Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38470545 DOI: 10.1158/1078-0432.CCR-23-2928 |
0.393 |
|
| 2024 |
Lawrence-Paul MR, Pan TC, Pant DK, Shih NNC, Chen Y, Belka GK, Feldman M, DeMichele A, Chodosh LA. Rare subclonal sequencing of breast cancers indicates putative metastatic driver mutations are predominately acquired after dissemination. Genome Medicine. 16: 26. PMID 38321573 DOI: 10.1186/s13073-024-01293-9 |
0.333 |
|
| 2024 |
Smith KL, Zhao F, Mayer IA, Tevaarwerk AJ, Garcia SF, Arteaga CL, Symmans WF, Park BH, Burnette BL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, ... ... DeMichele AM, et al. Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131. Cancer. PMID 38236702 DOI: 10.1002/cncr.35187 |
0.314 |
|
| 2023 |
Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chien AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, ... ... DeMichele AM, et al. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer. Jama Network Open. 6: e2349646. PMID 38153734 DOI: 10.1001/jamanetworkopen.2023.49646 |
0.437 |
|
| 2023 |
Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, ... ... DeMichele AM, et al. Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial - Efficacy and biomarker discovery. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38109213 DOI: 10.1158/1078-0432.CCR-22-2256 |
0.433 |
|
| 2023 |
Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP, Asare SM, Sit L, Matthews JB, Perlmutter J, ... ... DeMichele AM, et al. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial. Cell Reports. Medicine. 101312. PMID 38086377 DOI: 10.1016/j.xcrm.2023.101312 |
0.365 |
|
| 2023 |
Pfeiler G, Hlauschek D, Mayer EL, Deutschmann C, Kacerovsky-Strobl S, Martin M, Meisel JL, Zdenkowski N, Loibl S, Balic M, Park H, Prat A, Isaacs C, Bajetta E, Balko JM, ... ... DeMichele A, et al. Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2300126. PMID 37556775 DOI: 10.1200/JCO.23.00126 |
0.439 |
|
| 2023 |
DeMichele A, Robert N, Chen C, Kim S, Zhang Z, Lu DR, Aguilar KM, Wang Y, Li B, Schneeweiss S, Rassen JA, Gaffney M, McRoy L. Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer. Targeted Oncology. PMID 37428347 DOI: 10.1007/s11523-023-00979-1 |
0.422 |
|
| 2023 |
Burstein HJ, DeMichele A, Somerfield MR, Henry NL. Testing for Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2300638. PMID 37196213 DOI: 10.1200/JCO.23.00638 |
0.311 |
|
| 2023 |
Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, ... ... DeMichele AM, et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. PMID 37146605 DOI: 10.1016/j.ccell.2023.04.008 |
0.482 |
|
| 2023 |
Chitalia R, Miliotis M, Jahani N, Tastsoglou S, McDonald ES, Belenky V, Cohen EA, Newitt D, Van't Veer LJ, Esserman L, Hylton N, DeMichele A, Hatzigeorgiou A, Kontos D. Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy. Communications Medicine. 3: 46. PMID 36997615 DOI: 10.1038/s43856-023-00273-1 |
0.32 |
|
| 2023 |
Brown JC, Sturgeon K, Sarwer DB, Troxel AB, DeMichele AM, Denlinger CS, Schmitz KH. The effects of exercise and diet on oxidative stress and telomere length in breast cancer survivors. Breast Cancer Research and Treatment. PMID 36933050 DOI: 10.1007/s10549-023-06868-5 |
0.322 |
|
| 2023 |
Rugo HS, Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Cristofanilli M, Torres MA, Curigliano G, Finn RS, DeMichele A. Prolonging the life of people with metastatic breast cancer in routine clinical practice by adding palbociclib to an aromatase inhibitor from a real-world database analysis: a plain language summary. Future Oncology (London, England). PMID 36892508 DOI: 10.2217/fon-2022-1192 |
0.417 |
|
| 2023 |
Clark AS, Hong F, Finn RS, DeMichele AM, Mitchell EP, Zwiebel J, Arnaldez FI, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Copur MS, et al. Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF7. PMID 36853016 DOI: 10.1158/1078-0432.CCR-22-2150 |
0.309 |
|
| 2023 |
Magbanua MJM, van 't Veer L, Clark AS, Chien AJ, Boughey JC, Han HS, Wallace A, Beckwith H, Liu MC, Yau C, Wileyto EP, Ordonez A, Solanki TI, Hsiao F, Lee JC, ... ... DeMichele A, et al. Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study. Breast Cancer Research and Treatment. PMID 36689092 DOI: 10.1007/s10549-022-06803-0 |
0.326 |
|
| 2023 |
Chen S, Paul MR, Sterner CJ, Belka GK, Wang D, Xu P, Sreekumar A, Pan TC, Pant DK, Makhlin I, DeMichele A, Mesaros C, Chodosh LA. PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies. Breast Cancer Research : Bcr. 25: 1. PMID 36597146 DOI: 10.1186/s13058-022-01559-3 |
0.428 |
|
| 2022 |
Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, ... ... DeMichele AM, et al. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. Npj Breast Cancer. 8: 128. PMID 36456573 DOI: 10.1038/s41523-022-00493-z |
0.478 |
|
| 2022 |
Strand SH, Rivero-Gutiérrez B, Houlahan KE, Seoane JA, King LM, Risom T, Simpson LA, Vennam S, Khan A, Cisneros L, Hardman T, Harmon B, Couch F, Gallagher K, Kilgore M, ... ... DeMichele A, et al. Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts. Cancer Cell. PMID 36400020 DOI: 10.1016/j.ccell.2022.10.021 |
0.394 |
|
| 2022 |
Makhlin I, McAndrew NP, Wileyto EP, Clark AS, Holmes R, Bottalico LN, Mesaros C, Blair IA, Jeschke GR, Fox KR, Domchek SM, Matro JM, Bradbury AR, Feldman MD, Hexner EO, ... ... DeMichele A, et al. Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer. Npj Breast Cancer. 8: 122. PMID 36369506 DOI: 10.1038/s41523-022-00487-x |
0.391 |
|
| 2022 |
Rugo HS, Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Cristofanilli M, Torres MA, Curigliano G, Finn RS, DeMichele A. Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. Npj Breast Cancer. 8: 114. PMID 36220852 DOI: 10.1038/s41523-022-00479-x |
0.358 |
|
| 2022 |
Clark AS, Cobain EF, Dayao Z, Somerfield MR, DeMichele A, Henry NL. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update Q and A. Jco Oncology Practice. OP2200506. PMID 36122313 DOI: 10.1200/OP.22.00506 |
0.394 |
|
| 2022 |
Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, Moy B, Park BH, Shanahan KM, Sharma P, Shatsky R, Stringer-Reasor E, Telli M, Turner NC, DeMichele A. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2201063. PMID 35759724 DOI: 10.1200/JCO.22.01063 |
0.419 |
|
| 2022 |
Makhlin I, DeMichele A. Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer. Cell Reports. Medicine. 3: 100668. PMID 35732147 DOI: 10.1016/j.xcrm.2022.100668 |
0.442 |
|
| 2022 |
Cescon DW, Kalinsky K, DeMichele AM. Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2201026. PMID 35658519 DOI: 10.1200/JCO.22.01026 |
0.359 |
|
| 2022 |
Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher IR, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J, ... ... DeMichele AM, et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. PMID 35623341 DOI: 10.1016/j.ccell.2022.05.005 |
0.37 |
|
| 2022 |
Thakran S, Cohen E, Jahani N, Weinstein SP, Pantalone L, Hylton N, Newitt D, DeMichele A, Davatzikos C, Kontos D. Impact of deformable registration methods for prediction of recurrence free survival response to neoadjuvant chemotherapy in breast cancer: Results from the ISPY 1/ACRIN 6657 trial. Translational Oncology. 20: 101411. PMID 35395604 DOI: 10.1016/j.tranon.2022.101411 |
0.371 |
|
| 2022 |
Cescon DW, Kalinsky K, Parsons HA, Smith KL, Spears PA, Thomas A, Zhao F, DeMichele A. Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches. Frontiers in Oncology. 11: 667397. PMID 35223447 DOI: 10.3389/fonc.2021.667397 |
0.368 |
|
| 2022 |
Mayer EL, Fesl C, Hlauschek D, Garcia-Estevez L, Burstein HJ, Zdenkowski N, Wette V, Miller KD, Balic M, Mayer IA, Cameron D, Winer EP, Ponce Lorenzo JJ, Lake D, Pristauz-Telsnigg G, ... ... DeMichele A, et al. Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2101918. PMID 34995105 DOI: 10.1200/JCO.21.01918 |
0.346 |
|
| 2021 |
Thompson EW, Demissei BG, Smith AM, Brahmbhatt P, Wang J, Clark A, DeMichele A, Narayan V, Shah P, Sun L, Lefebvre B, Fradley MG, Carver JR, Tang WHW, Ky B. Paraoxonase-1 Activity in Breast Cancer Patients Treated With Doxorubicin With or Without Trastuzumab. Jacc. Basic to Translational Science. 7: 1-10. PMID 35128203 DOI: 10.1016/j.jacbts.2021.10.010 |
0.358 |
|
| 2021 |
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, ... ... DeMichele AM, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. The Lancet. Oncology. PMID 34902335 DOI: 10.1016/S1470-2045(21)00589-1 |
0.442 |
|
| 2021 |
Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga JM, Rubovsky G, ... ... DeMichele A, et al. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2102554. PMID 34874182 DOI: 10.1200/JCO.21.02554 |
0.468 |
|
| 2021 |
Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, ... ... DeMichele AM, et al. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2 breast cancer in the adaptively randomized I-SPY2 trial. Nature Communications. 12: 6428. PMID 34741023 DOI: 10.1038/s41467-021-26019-y |
0.427 |
|
| 2021 |
Engebraaten O, Yau C, Berg K, Borgen E, Garred Ø, Berstad MEB, Fremstedal ASV, DeMichele A, Veer LV', Esserman L, Weyergang A. RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer. Nature Communications. 12: 6427. PMID 34741021 DOI: 10.1038/s41467-021-26018-z |
0.324 |
|
| 2021 |
Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, ... ... DeMichele A, et al. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. Npj Breast Cancer. 7: 131. PMID 34611148 DOI: 10.1038/s41523-021-00337-2 |
0.363 |
|
| 2021 |
Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, ... ... DeMichele AM, et al. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. Jama Oncology. PMID 34529000 DOI: 10.1001/jamaoncol.2021.3690 |
0.458 |
|
| 2021 |
Onishi N, Li W, Newitt DC, Harnish RJ, Strand F, Nguyen AA, Arasu VA, Gibbs J, Jones EF, Wilmes LJ, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, ... ... DeMichele A, et al. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. Radiology. 203645. PMID 34427465 DOI: 10.1148/radiol.2021203645 |
0.329 |
|
| 2021 |
Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, ... ... DeMichele AM, et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. PMID 34143979 DOI: 10.1016/j.ccell.2021.05.009 |
0.447 |
|
| 2021 |
Paoletti C, Regan MM, Niman SM, Dolce EM, Darga EP, Liu MC, Marcom PK, Hart LL, Smith JW, Tedesco KL, Amir E, Krop IE, DeMichele AM, Goodwin PJ, Block M, et al. Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. Npj Breast Cancer. 7: 77. PMID 34117261 DOI: 10.1038/s41523-021-00281-1 |
0.341 |
|
| 2021 |
Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, ... ... DeMichele AM, et al. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2100976. PMID 34092112 DOI: 10.1200/JCO.21.00976 |
0.446 |
|
| 2021 |
Brown JC, Sarwer DB, Troxel AB, Sturgeon K, DeMichele AM, Denlinger CS, Schmitz KH. A randomized trial of exercise and diet on body composition in survivors of breast cancer with overweight or obesity. Breast Cancer Research and Treatment. PMID 34089422 DOI: 10.1007/s10549-021-06284-7 |
0.335 |
|
| 2021 |
Rugo HS, Cristofanilli M, Loibl S, Harbeck N, DeMichele A, Iwata H, Park YH, Brufsky A, Theall KP, Huang X, McRoy L, Bananis E, Turner NC. Prognostic Factors for Overall Survival in Patients With Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3. The Oncologist. PMID 34037282 DOI: 10.1002/onco.13833 |
0.439 |
|
| 2021 |
Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, Greenplate AR, Hwee MA, Porterfield F, Owoyemi O, Naik K, Zheng C, Galantino M, Weisman AR, Ittner CAG, ... ... DeMichele AM, et al. CD8 T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nature Medicine. PMID 34017137 DOI: 10.1038/s41591-021-01386-7 |
0.304 |
|
| 2021 |
Rocque GB, Williams CP, Andrews C, Childers TC, Wiseman KD, Gallagher K, Tung N, Balch A, Lawhon VM, Ingram SA, Brown T, Kaufmann T, Smith ML, DeMichele A, Wolff AC, et al. Patient perspectives on chemotherapy de-escalation in breast cancer. Cancer Medicine. PMID 33932097 DOI: 10.1002/cam4.3891 |
0.461 |
|
| 2021 |
DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, Layman RM, Emir B, Torres MA, Rugo HS, Finn RS. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Research : Bcr. 23: 37. PMID 33761995 DOI: 10.1186/s13058-021-01409-8 |
0.383 |
|
| 2021 |
Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley D, Karuturi MS, Sanft T, Blau S, Hart L, Ma CX, Rugo HS, Purkayastha D, Moulder-Thompson S. Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33722897 DOI: 10.1158/1078-0432.CCR-20-2114 |
0.367 |
|
| 2021 |
Sun L, Surya S, Le AN, Desai H, Doucette A, Gabriel P, Ritchie MD, Rader D, Maillard I, Bange E, Huang AC, Vonderheide RH, DeMichele A, Verma A, Mamtani R, et al. Rates of COVID-19-Related Outcomes in Cancer Compared With Noncancer Patients. Jnci Cancer Spectrum. 5: pkaa120. PMID 33554040 DOI: 10.1093/jncics/pkaa120 |
0.317 |
|
| 2021 |
McAndrew NP, Bottalico L, Mesaros C, Blair IA, Tsao PY, Rosado JM, Ganguly T, Song SJ, Gimotty PA, Mao JJ, DeMichele A. Effects of systemic inflammation on relapse in early breast cancer. Npj Breast Cancer. 7: 7. PMID 33483516 DOI: 10.1038/s41523-020-00212-6 |
0.405 |
|
| 2021 |
Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, ... ... DeMichele A, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. The Lancet. Oncology. PMID 33460574 DOI: 10.1016/S1470-2045(20)30642-2 |
0.429 |
|
| 2020 |
Makhlin I, DeMichele A. On the Rise of Cyclin-Dependent Kinase Inhibitors in Breast Cancer: . Breast Cancer Management. 9. PMID 34475968 DOI: 10.2217/bmt-2020-0005 |
0.374 |
|
| 2020 |
Maxwell KN, Wenz BM, Kulkarni A, Wubbenhorst B, D'Andrea K, Weathers B, Goodman N, Vijai J, Lilyquist J, Hart SN, Slavin TP, Schrader KA, Ravichandran V, Thomas T, Hu C, ... ... DeMichele AM, et al. Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. Jco Precision Oncology. 4. PMID 32954205 DOI: 10.1200/PO.19.00301 |
0.457 |
|
| 2020 |
Sun L, Sanjna S, Le A, Desai H, Doucette A, Gabriel P, Ritchie M, Rader D, Maillard I, Bange E, Huang A, Vonderheide RH, DeMichele A, Verma A, Mamtani R, et al. Rates of COVID-19-related Outcomes in Cancer compared to non-Cancer Patients. Medrxiv : the Preprint Server For Health Sciences. PMID 32817956 DOI: 10.1101/2020.08.14.20174961 |
0.329 |
|
| 2020 |
Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, et al. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. Jama Oncology. PMID 32701140 DOI: 10.1001/Jamaoncol.2020.2535 |
0.313 |
|
| 2020 |
Paul MR, Pan TC, Pant DK, Shih NN, Chen Y, Harvey KL, Solomon A, Lieberman D, Morrissette JJ, Soucier-Ernst D, Goodman NG, Stavropoulos SW, Maxwell KN, Clark C, Belka GK, ... ... DeMichele A, et al. Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets. The Journal of Clinical Investigation. PMID 32657779 DOI: 10.1172/Jci129941 |
0.438 |
|
| 2020 |
McAndrew NP, Dickson MA, Clark AS, Troxel AB, O'Hara MH, Colameco C, Gallager M, Gramlich K, Zafman K, Vaughn D, Schwartz GK, O'Dwyer PJ, DeMichele A. Early treatment-related neutropenia predicts response to palbociclib. British Journal of Cancer. PMID 32641862 DOI: 10.1038/S41416-020-0967-7 |
0.463 |
|
| 2020 |
Charo LM, Homer MV, Natarajan L, Haunschild C, Chung K, Mao JJ, DeMichele AM, Su HI. Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors. Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology. 1-6. PMID 32496149 DOI: 10.1080/01443615.2020.1754369 |
0.435 |
|
| 2020 |
Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, ... ... DeMichele A, et al. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. Jama Oncology. PMID 32053137 DOI: 10.1001/Jamaoncol.2019.6650 |
0.537 |
|
| 2020 |
Demissei BG, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, Narayan V, Domchek SM, DeMichele A, Shah P, Clark AS, Fox K, Matro J, Bradbury AR, Knollman H, et al. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. Journal of the American Heart Association. 9: e014708. PMID 31959034 DOI: 10.1161/Jaha.119.014708 |
0.489 |
|
| 2020 |
Makhlin I, DeMichele A. On the rise of cyclin-dependent kinase inhibitors in breast cancer: progress and ongoing challenges Breast Cancer Management. 9. DOI: 10.2217/Bmt-2020-0005 |
0.477 |
|
| 2020 |
Martei YM, Grover S, Narasimhamurthy M, Setlhako DII, Ayane GN, Ralefala TB, Chiyapo SP, Gross R, DeMichele A, Shulman LN. Relative dose intensity and pathologic response rates in HIV-infected and HIV-uninfected breast cancer patients who received neoadjuvant chemotherapy. Journal of Clinical Oncology. 38: e19140-e19140. DOI: 10.1200/Jco.2020.38.15_Suppl.E19140 |
0.381 |
|
| 2020 |
Bradbury AR, Lee J, Gaieski JB, Li S, Gareen IF, Flaherty K, Herman BA, DeMichele A, Domchek SM, Maxwell KN, Onitilo AA, Virani S, Park S, Faller BA, Grant SC, et al. Randomized trial of web-based genetic education versus usual care in advanced cancer patients undergoing tumor genetic testing: Results from the ECOG-ACRIN NCI Community Oncology Research Program (NCORP; EAQ152) COMET trial. Journal of Clinical Oncology. 38: 2008-2008. DOI: 10.1200/Jco.2020.38.15_Suppl.2008 |
0.343 |
|
| 2020 |
Li W, Onishi N, Newitt DC, Gibbs J, Wilmes LJ, Jones EF, Joe BN, Sit LS, Yau C, Chien AJ, Price E, Albain KS, Kuritza T, Morley K, Boughey JC, ... ... DeMichele A, et al. Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd9-04 |
0.411 |
|
| 2020 |
Pohlmann PR, Yau C, DeMichele A, Isaacs C, Boughey JC, Hylton N, Melisko ME, Perlmutter J, Rugo HS, Symmans WF, Berry DA, Esserman L. Abstract P6-10-06: Amsterdam 70-gene profile (MammaPrint) low risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-10-06 |
0.452 |
|
| 2020 |
Li W, Onishi N, Newitt DC, Harnish R, Jones EF, Wilmes LJ, Gibbs J, Price E, Joe BN, Chien AJ, Berry DA, Boughey JC, Albain KS, Clark AS, Edmiston KK, ... ... DeMichele A, et al. Abstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-02-01 |
0.44 |
|
| 2020 |
Magbanua MJM, Brown-Swigart L, Hirst G, Yau C, Wolf D, Wu H, Tin A, Shchegrova S, Sethi H, Salari R, Aleshin A, Louie M, Zimmermann B, DeMichele A, Liu M, et al. Abstract P5-01-04: Personalized monitoring of circulating tumor DNA during neoadjuvant therapy in high-risk early stage breast cancer reflects response and risk of metastatic recurrence Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P5-01-04 |
0.44 |
|
| 2020 |
Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Asare SM, Hirst GL, Sit L, Perlmutter J, Liu M, Park J, DeMichele A, Yee D, Berry D, Esserman L, Petricoin E, et al. Abstract P4-10-02: HER2 signaling, ER, and proliferation biomarkers predict response to multiple HER2-targeted agents/combinations plus standard neoadjuvant therapy in the I-SPY 2 trial Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P4-10-02 |
0.347 |
|
| 2020 |
Helsten TL, Lo SS, Yau C, Kalinsky K, Elias AD, Wallace AM, Chien AJ, Lu J, Lang JE, Albain KS, Stringer-Reasor E, Clark AS, Boughey JC, Ellis ED, Yee D, ... DeMichele A, et al. Abstract P3-11-02: Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoadjuvant I-SPY 2 trial Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-11-02 |
0.529 |
|
| 2020 |
Liu MC, Robinson PA, Yau C, Wallace AM, Chien AJ, Stringer-Reasor E, Nanda R, Yee D, Albain KS, Boughey JC, Han HS, Elias AD, Kalinsky K, Clark AS, Kemmer K, ... ... DeMichele A, et al. Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P3-09-02 |
0.507 |
|
| 2020 |
Yau C, DeMichele A, Symmans WF, Pusztai L, Yee D, Clark AS, Hatzis C, Matthews JB, Carter J, Chen Y, Cole K, Khazai L, Klein M, Kokh D, Krings G, et al. Abstract P2-20-02: Site of recurrence after neoadjuvant therapy: Clues to biology and impact on endpoints Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P2-20-02 |
0.404 |
|
| 2020 |
Nivar I, Kauffman T, Bayne L, Wiley P, Goodspeed B, Feldman M, Chodosh L, Clark A, DeMichele A. Abstract P2-12-01: Patient attitudes, experience and results of screening for minimal residual disease (MRD) for therapeutic intervention Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P2-12-01 |
0.418 |
|
| 2020 |
DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, Layman RM, Rugo HS, Finn RS. Abstract P1-19-02: Overall survival for first-line palbociclib plus letrozole vs letrozole alone for HR+/HER2- metastatic breast cancer patients in US real-world clinical practice Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P1-19-02 |
0.389 |
|
| 2019 |
Dowling RJO, Kalinsky K, Hayes DF, Bidard FC, Cescon DW, Chandarlapaty S, Deasy JO, Dowsett M, Gray RJ, Henry NL, Meric-Bernstam F, Perlmutter J, Sledge GW, Bratman SV, Carey LA, ... ... DeMichele A, et al. Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. Jnci Cancer Spectrum. 3: pkz050. PMID 32337479 DOI: 10.1093/Jncics/Pkz050 |
0.457 |
|
| 2019 |
Dowling RJO, Sparano JA, Goodwin PJ, Bidard FC, Cescon DW, Chandarlapaty S, Deasy JO, Dowsett M, Gray RJ, Henry NL, Meric-Bernstam F, Perlmutter J, Sledge GW, Thorat MA, Bratman SV, ... ... DeMichele A, et al. Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. Jnci Cancer Spectrum. 3: pkz049. PMID 32337478 DOI: 10.1093/Jncics/Pkz049 |
0.457 |
|
| 2019 |
Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, ... ... DeMichele A, et al. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901027. PMID 32031889 DOI: 10.1200/Jco.19.01027 |
0.554 |
|
| 2019 |
McDonald ES, Doot RK, Young AJ, Schubert EK, Pryma DA, Farwell MD, Tchou J, Nayak A, Ziober A, Feldman MD, DeMichele A, Clark AS, Shah PD, Lee H, Carlin SD, et al. Breast Cancer F-ISO-1 Uptake as a Marker of Proliferation Status. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31836680 DOI: 10.2967/Jnumed.119.232363 |
0.46 |
|
| 2019 |
Upshaw JN, Finkelman B, Hubbard RA, Smith AM, Narayan HK, Arndt L, Domchek S, DeMichele A, Fox K, Shah P, Clark A, Bradbury A, Matro J, Adusumalli S, Carver JR, et al. Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy. Jacc. Cardiovascular Imaging. PMID 31542526 DOI: 10.1016/J.Jcmg.2019.07.018 |
0.41 |
|
| 2019 |
Gelmon KA, Cristofanilli M, Rugo HS, DeMichele AM, Joy AA, Castrellon A, Sleckman B, Mori A, Theall KP, Lu DR, Huang X, Bananis E, Finn RS, Slamon DJ. Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. The Breast Journal. PMID 31448513 DOI: 10.1111/Tbj.13516 |
0.391 |
|
| 2019 |
Schmitz KH, Troxel AB, Dean LT, DeMichele A, Brown JC, Sturgeon K, Zhang Z, Evangelisti M, Spinelli B, Kallan MJ, Denlinger C, Cheville A, Winkels RM, Chodosh L, Sarwer DB. Effect of Home-Based Exercise and Weight Loss Programs on Breast Cancer-Related Lymphedema Outcomes Among Overweight Breast Cancer Survivors: The WISER Survivor Randomized Clinical Trial. Jama Oncology. PMID 31415063 DOI: 10.1001/Jamaoncol.2019.2109 |
0.43 |
|
| 2019 |
Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Bartlett CH, Koehler M, Winer EP, Burstein HJ. A Phase II Feasibility Study of Palbociclib in Combination with Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31250880 DOI: 10.1093/Annonc/Mdz198 |
0.511 |
|
| 2019 |
Demissei BG, Finkelman BS, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, Narayan HK, Narayan V, Waxman AJ, Domchek SM, DeMichele A, Shah P, Clark AS, Bradbury AR, et al. Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy. Cancer. PMID 31042319 DOI: 10.1002/Cncr.32149 |
0.447 |
|
| 2019 |
Martei YM, Grover S, Bilker WB, Monare B, Setlhako DI, Ralefala TB, Manshimba P, Gross R, Shulman LN, DeMichele A. Impact of Essential Medicine Stock Outs on Cancer Therapy Delivery in a Resource-Limited Setting. Journal of Global Oncology. 5: 1-11. PMID 30969808 DOI: 10.1200/Jgo.18.00230 |
0.407 |
|
| 2019 |
Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, DeMichele A, Harbeck N, André F, Bayar MA, Michiels S, Zhang Z, Giorgetti C, Arnedos M, Huang Bartlett C, et al. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1800925. PMID 30807234 DOI: 10.1200/Jco.18.00925 |
0.449 |
|
| 2019 |
Clark AS, McAndrew NP, Troxel A, Feldman M, Lal P, Rosen M, Burrell J, Redlinger C, Gallgher M, Bradbury AR, Domchek SM, Fox KR, O'Dwyer PJ, DeMichele AM. Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30635336 DOI: 10.1158/1078-0432.Ccr-18-0790 |
0.413 |
|
| 2019 |
Kaufmann TL, Hsu JY, Getz KD, Kamal A, DeMichele A. Patient-reported symptom profiles: A tool to direct palliative care referral. Journal of Clinical Oncology. 37: 93-93. DOI: 10.1200/Jco.2019.37.31_Suppl.93 |
0.329 |
|
| 2019 |
Davey S, Grover S, Setlhako DII, Ralefala TB, Manshimba P, Gross R, DeMichele A, Shulman LN, Martei YM, Bilker WB. Prescription patterns and associated cost during periods of cancer drug stockouts in a resource-limited setting. Journal of Clinical Oncology. 37: e18129-e18129. DOI: 10.1200/Jco.2019.37.15_Suppl.E18129 |
0.428 |
|
| 2019 |
Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak AB, Yardley DA, Karuturi MS, Sanft TB, Blau S, Hart LL, Ma CX, Caria N, Purkayastha DD, Mistry A, Moulder SL. Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results. Journal of Clinical Oncology. 37: 1016-1016. DOI: 10.1200/Jco.2019.37.15_Suppl.1016 |
0.437 |
|
| 2019 |
Finn R, Turner N, Liu Y, Rugo H, Loibl S, Diéras V, Slamon D, André F, Gelmon K, DeMichele A, Loi S, Zhang Z, Giorgetti C, Gauthier E, Bartlett CH, et al. Abstract P6-18-03: Biomarker analysis of CDK 4/6 and endocrine pathways in hormone-receptor positive (HR+) advanced breast cancer (ABC) bone only disease patients: A joint analysis of PALOMA-2 and PALOMA-3 studies Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P6-18-03 |
0.385 |
|
| 2019 |
Hylton N, Symmans W, Yau C, Li W, Hatzis C, Isaacs C, Albain K, Chen Y, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, ... ... DeMichele A, et al. Abstract P2-07-03: Refining neoadjuvant predictors of three year distant metastasis free survival: Integrating volume change as measured by MRI with residual cancer burden Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P2-07-03 |
0.365 |
|
| 2019 |
Schwab R, Clark AS, Yau C, Hylton N, Li W, Wolfe D, Chien AJ, Wallace AM, Forero-Torres A, Stringer-Reasor E, Nanda R, Jaskowiak N, Boughey J, Haddad T, Han HS, ... ... DeMichele A, et al. Abstract CT136: Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct136 |
0.499 |
|
| 2019 |
Wolf DM, Yau C, Wulfkuhle J, Petricoin E, Brown-Swigart L, Hirst G, Asare S, Yee D, DeMichele A, Rugo H, Olopade O, Nanda R, Liu M, Esserman L, Veer Lvt. Abstract 2679: Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum-containing regimens vs. immunotherapy: The neoadjuvant I-SPY 2 trial Cancer Research. 79: 2679-2679. DOI: 10.1158/1538-7445.Am2019-2679 |
0.402 |
|
| 2019 |
Upshaw J, Finkelman B, Hubbard R, Smith A, Narayan H, Arndt L, Domchek S, DeMichele A, Fox K, Shah P, Clark A, Bradbury A, Matro J, Adusumalli S, Carver J, et al. CHANGES IN LEFT VENTRICULAR DIASTOLIC FUNCTION WITH CONTEMPORARY BREAST CANCER THERAPY Journal of the American College of Cardiology. 73: 1676. DOI: 10.1016/S0735-1097(19)32282-X |
0.455 |
|
| 2019 |
Demissei B, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, Narayan V, Domchek SM, DeMichele A, Shah P, Clark AS, Fox K, Matro J, Bradbury AR, Knollman H, et al. Changes In Cardiovascular Biomarkers With Breast Cancer Therapy And Associations With Cardiac Dysfunction Journal of the American College of Cardiology. 73: 678. DOI: 10.1016/S0735-1097(19)31286-0 |
0.453 |
|
| 2018 |
Cristofanilli M, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall K, et al. Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii708. PMID 32137965 DOI: 10.1093/Annonc/Mdy424.009 |
0.442 |
|
| 2018 |
Loibl S, Metzger O, Mandrekar SJ, Mundhenke C, Seiler S, Valagussa P, DeMichele A, Lim E, Tripathy D, Winer EP, Huang C, Carey L, Francis P, Miller KD, Goetz MP, et al. PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii121. PMID 32136159 DOI: 10.1093/Annonc/Mdy272.357 |
0.438 |
|
| 2018 |
Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall K, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. The New England Journal of Medicine. PMID 30345905 DOI: 10.1056/Nejmoa1810527 |
0.5 |
|
| 2018 |
Maity A, Mick R, Huang AC, George SM, Farwell MD, Lukens JN, Berman AT, Mitchell TC, Bauml J, Schuchter LM, O'Hara M, Lin LL, Demichele A, Christodouleas JP, Haas NB, et al. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. British Journal of Cancer. PMID 30318516 DOI: 10.1038/S41416-018-0281-9 |
0.384 |
|
| 2018 |
Cristofanilli M, DeMichele A, Giorgetti C, Turner NC, Slamon DJ, Im SA, Masuda N, Verma S, Loi S, Colleoni M, Theall KP, Huang X, Liu Y, Bartlett CH. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. European Journal of Cancer (Oxford, England : 1990). 104: 21-31. PMID 30308388 DOI: 10.1016/J.Ejca.2018.08.011 |
0.51 |
|
| 2018 |
Banerjee S, Tian T, Wei Z, Shih N, Feldman MD, Peck KN, DeMichele AM, Alwine JC, Robertson ES. Distinct Microbial Signatures Associated With Different Breast Cancer Types. Frontiers in Microbiology. 9: 951. PMID 29867857 DOI: 10.3389/Fmicb.2018.00951 |
0.447 |
|
| 2018 |
O'Shaughnessy J, DeMichele A, Ma CX, Richards P, Yardley DA, Wright GS, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo HS. A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast Cancer Research and Treatment. PMID 29675680 DOI: 10.1007/S10549-018-4770-6 |
0.488 |
|
| 2018 |
McAndrew N, DeMichele A. Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer. The Journal of Targeted Therapies in Cancer. 7: 52-69. PMID 29577076 |
0.379 |
|
| 2018 |
Turner NC, Finn RS, Martin M, Im SA, DeMichele A, Ettl J, Diéras V, Moulder S, Lipatov O, Colleoni M, Cristofanilli M, Lu DR, Mori A, Giorgetti C, Iyer S, et al. Clinical Considerations of the Role of Palbociclib in the Management of Advanced Breast Cancer Patients With and Without Visceral Metastases. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29342248 DOI: 10.1093/Annonc/Mdx797 |
0.52 |
|
| 2018 |
Martei Y, Grover S, Bilker W, Setlhako D, Ralefala T, Manshimba P, Gross R, Shulman L, DeMichele A. Impact of Chemotherapy Stock-Out on Standard Therapy Delivery Among Cancer Patients in Botswana Journal of Global Oncology. 4. DOI: 10.1200/Jgo.18.30500 |
0.475 |
|
| 2018 |
Tannir NM, Fan AC, Lee RJ, Carthon BC, Iliopoulos O, Mier JW, Patel MR, Meric-Bernstam F, DeMichele A, Voss MH, Harding JJ, Srinivasan R, Shapiro G, Telli ML, Munster PN, et al. Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC). Journal of Clinical Oncology. 36: 603-603. DOI: 10.1200/Jco.2018.36.6_Suppl.603 |
0.336 |
|
| 2018 |
Mayer EL, Wander SA, Regan MM, DeMichele A, Forero-Torres A, Rimawi MF, Ma CX, Cristofanilli M, Anders CK, Bartlett CH, Winer EP, Burstein HJ. Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer. Journal of Clinical Oncology. 36: TPS1104-TPS1104. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps1104 |
0.468 |
|
| 2018 |
Symmans WF, Yau C, Chen Y, Datnow B, Wei S, Feldman MD, Ritter J, Duan X, Chen B, Tickman R, Sattar H, Magliocco AM, Kallakury B, Troxell M, Asare S, ... ... DeMichele A, et al. Residual cancer burden (RCB) as prognostic in the I-SPY 2 TRIAL. Journal of Clinical Oncology. 36: 520-520. DOI: 10.1200/Jco.2018.36.15_Suppl.520 |
0.485 |
|
| 2018 |
Maxwell KN, Vijai J, Lilyquist J, Slavin TP, Kulkarni A, Vaccaro O, Wubbenhorst B, Neuhausen SL, Hart S, Ravichandran V, Thomas T, Hu C, Schrader KA, DeMichele A, Offit K, et al. Inherited mutations in breast cancer patients with and without multiple primary cancers. Journal of Clinical Oncology. 36: 1503-1503. DOI: 10.1200/Jco.2018.36.15_Suppl.1503 |
0.519 |
|
| 2018 |
McAndrew NP, Dickson MA, Clark AS, Troxel A, Colameco C, Gallagher M, Gramlich K, Zafman K, Vaughn DJ, Schwartz GK, O'Dwyer PJ, DeMichele A. Neutropenia and response to single agent palbociclib. Journal of Clinical Oncology. 36: 1043-1043. DOI: 10.1200/Jco.2018.36.15_Suppl.1043 |
0.525 |
|
| 2018 |
Metzger O, Mandrekar S, Loibl S, Mundhenke C, Seiler S, Valagussa P, Lim E, Tripathy D, Winer E, Huang C, Carey L, Francis P, Miller K, Goetz M, Prat A, ... ... DeMichele A, et al. Abstract OT3-05-07: PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Ot3-05-07 |
0.492 |
|
| 2018 |
Moulder S, Karuturi M, Yardley DA, Wright GS, Hurvitz S, Moroose R, Sanft T, Ma C, Zelnak A, DeMichele A, Clark A, Purkayastha D, Khullar A, Caria N, Bardia A. Abstract CT107: Ribociclib in combination with everolimus and exemestane in men and postmenopausal women with HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Efficacy and safety results from phase II of the TRINITI-1 study Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct107 |
0.461 |
|
| 2018 |
Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, DeMichele A, Harbeck N, André F, Zhang Z, Giorgetti C, Bartlett CH, Cristofanilli M. Abstract CT039: Cyclin E1 (CCNE1) expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct039 |
0.387 |
|
| 2018 |
Lee PRE, Zhu Z, Wolf D, Yau C, Audeh W, Glas A, Brown-Swigart L, Hirst G, DeMichele A, Investigators IT, Esserman L, Veer Lv'. Abstract 2612: BluePrint Luminal subtype predicts non-response to HER2-targeted therapies in HR+/HER2+ I-SPY 2 breast cancer patients Cancer Research. 78: 2612-2612. DOI: 10.1158/1538-7445.Am2018-2612 |
0.441 |
|
| 2018 |
Maity A, Mick R, Huang AC, George SM, Farwell MD, Lukens JN, Berman AT, Mitchell TC, Bauml J, Schuchter LM, O'Hara M, Lin LL, DeMichele A, Christodouleas JP, Haas NB, et al. A Phase I Trial of Pembrolizumab with Hypofractionated Radiation Therapy (HFRT) in Patients with Metastatic Cancers International Journal of Radiation Oncology Biology Physics. 102. DOI: 10.1016/J.Ijrobp.2018.06.147 |
0.402 |
|
| 2017 |
DeMichele A, Yee D, Esserman L. Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer. The New England Journal of Medicine. 377: 2287-2289. PMID 29211674 DOI: 10.1056/Nejmcibr1711545 |
0.549 |
|
| 2017 |
Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, et al. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. Npj Breast Cancer. 3: 31. PMID 28948212 DOI: 10.1038/s41523-017-0025-7 |
0.328 |
|
| 2017 |
Lowenfeld L, Zaheer S, Oechsle C, Fracol M, Datta J, Xu S, Fitzpatrick E, Roses RE, Fisher CS, McDonald ES, Zhang PJ, DeMichele A, Mick R, Koski GK, Czerniecki BJ. Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ER(pos)/HER2(pos) early breast cancer. Oncoimmunology. 6: e1207032. PMID 28932627 DOI: 10.1080/2162402X.2016.1207032 |
0.425 |
|
| 2017 |
Sturgeon KM, Hackley R, Fornash A, Dean LT, Laudermilk M, Brown JC, Sarwer DB, DeMichele AM, Troxel AB, Schmitz KH. Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer. PMID 28881471 DOI: 10.1002/Cncr.30935 |
0.513 |
|
| 2017 |
Winkels RM, Sturgeon KM, Kallan MJ, Dean LT, Zhang Z, Evangelisti M, Brown JC, Sarwer DB, Troxel AB, Denlinger C, Laudermilk M, Fornash A, DeMichele A, Chodosh LA, Schmitz KH. The women in steady exercise research (WISER) survivor trial: The innovative transdisciplinary design of a randomized controlled trial of exercise and weight-loss interventions among breast cancer survivors with lymphedema. Contemporary Clinical Trials. PMID 28739540 DOI: 10.1016/J.Cct.2017.07.017 |
0.456 |
|
| 2017 |
Patel SA, DeMichele A. Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data. Current Oncology Reports. 19: 56. PMID 28733827 DOI: 10.1007/S11912-017-0613-6 |
0.453 |
|
| 2017 |
Finkelman BS, Putt M, Wang T, Wang L, Narayan H, Domchek S, DeMichele A, Fox K, Matro J, Shah P, Clark A, Bradbury A, Narayan V, Carver JR, Tang WHW, et al. Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer. Journal of the American College of Cardiology. 70: 152-162. PMID 28683962 DOI: 10.1016/J.Jacc.2017.05.019 |
0.367 |
|
| 2017 |
Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, Colameco C, Kakrecha B, Langer M, Lieberman D, Morrissette JJD, Paul MR, Pan TC, Yee S, Shih N, ... ... DeMichele A, et al. Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer. Breast Cancer Research and Treatment. PMID 28653249 DOI: 10.1007/S10549-017-4339-9 |
0.485 |
|
| 2017 |
Henry NL, Bedard PL, DeMichele A. Standard and Genomic Tools for Decision Support in Breast Cancer Treatment. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 37: 106-115. PMID 28561710 DOI: 10.1200/EDBK_175617 |
0.363 |
|
| 2017 |
Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, Colameco C, Kakrecha B, Langer M, Lieberman D, Morrissette JJD, Paul MR, Pan TC, Yee S, Shih N, ... ... DeMichele A, et al. Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer. Breast Cancer Research and Treatment. PMID 28500398 DOI: 10.1007/s10549-017-4257-x |
0.386 |
|
| 2017 |
Sun W, O'Dwyer PJ, Finn RS, Ruiz-Garcia A, Shapiro GI, Schwartz GK, DeMichele A, Wang D. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach. Journal of Clinical Pharmacology. PMID 28419480 DOI: 10.1002/Jcph.902 |
0.407 |
|
| 2017 |
Palmer SC, Stricker CT, DeMichele AM, Schapira M, Glanz K, Griggs JJ, Jacobs LA. The use of a patient-reported outcome questionnaire to assess cancer survivorship concerns and psychosocial outcomes among recent survivors. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 28233121 DOI: 10.1007/S00520-017-3646-3 |
0.351 |
|
| 2017 |
Homer MV, Charo LM, Natarajan L, Haunschild C, Chung K, Mao JJ, DeMichele AM, Su HI. Genetic variants of age at menopause are not related to timing of ovarian failure in breast cancer survivors. Menopause (New York, N.Y.). PMID 28118297 DOI: 10.1097/GME.0000000000000817 |
0.348 |
|
| 2017 |
Nanda R, Liu MC, Yau C, Asare S, Hylton N, Veer LV, Perlmutter J, Wallace AM, Chien AJ, Forero-Torres A, Ellis E, Han H, Sanders Clark A, Albain KS, Caroline Boughey J, ... ... DeMichele A, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. Journal of Clinical Oncology. 35: 506-506. DOI: 10.1200/Jco.2017.35.15_Suppl.506 |
0.4 |
|
| 2017 |
DeMichele A, Harding J, Telli M, Münster P, McKay R, Iliopoulos O, Whiting S, Orford K, Bennett M, Mier J, Owonikoko T, Patel, Kalinsky K, Carvajal R, Infante J, et al. Abstract P6-11-05: Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pac) in patients (its) with triple negative breast cancer (TNBC) Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-11-05 |
0.422 |
|
| 2017 |
Paoletti C, Regan M, Liu M, Marcom P, Hart L, Smith J, Tedesco K, Amir E, Krop I, DeMichele A, Goodwin P, Block M, Aung K, Cannell E, Darga E, et al. Abstract P1-01-01: Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-01-01 |
0.499 |
|
| 2017 |
Hurvitz S, Yardley D, Zelnak A, DeMichele A, Tan-Chiu E, Ma C, Small T, Tucci C, Samant T, Purkayastha D, Moulder S, Bardia A. Abstract CT110: Ribociclib in combination with everolimus and exemestane in men and postmenopausal women with HR+/HER2− advanced breast cancer following progression on a CDK4/6 inhibitor: Safety, tolerability, and pharmacokinetic results from Phase 1 of TRINITI-1 study Clinical Trials. 77. DOI: 10.1158/1538-7445.Am2017-Ct110 |
0.455 |
|
| 2017 |
Harbeck N, Colleoni M, Demichele A, Turner NC, Cristofanilli M, Verma S, Sleckman B, Huang X, Theall KP, Bananis E, Masuda N, Im S. Efficacyand Safety of Palbociclib (PAL) PUS Fulvestrant (F) by Geographic Region in Women with Endocrine-Resistant Hormone Receptor-Positive (HR+), Human Epiderman Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer (ABC) from Paloma-3 The Breast. 36: S47. DOI: 10.1016/S0960-9776(17)30692-6 |
0.422 |
|
| 2017 |
Martei YM, DeMichele A. Neoadjuvant Therapy for Breast Cancer: State of the Science and Future Directions Current Breast Cancer Reports. 9: 1-12. DOI: 10.1007/S12609-017-0235-X |
0.519 |
|
| 2016 |
Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, et al. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. The New England Journal of Medicine. 375: 23-34. PMID 27406347 DOI: 10.1056/Nejmoa1513749 |
0.563 |
|
| 2016 |
Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, et al. Adaptive Randomization of Neratinib in Early Breast Cancer. The New England Journal of Medicine. 375: 11-22. PMID 27406346 DOI: 10.1056/Nejmoa1513750 |
0.552 |
|
| 2016 |
Verma S, Bartlett CH, Schnell P, DeMichele AM, Loi S, Ro J, Colleoni M, Iwata H, Harbeck N, Cristofanilli M, Zhang K, Thiele A, Turner NC, Rugo HS. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). The Oncologist. PMID 27368881 DOI: 10.1634/theoncologist.2016-0097 |
0.391 |
|
| 2016 |
Lee I, Garland SN, DeMichele A, Farrar JT, Im EO, Mao JJ. A cross-sectional survey of pain catastrophising and acupuncture use among breast cancer survivors. Acupuncture in Medicine : Journal of the British Medical Acupuncture Society. PMID 27177930 DOI: 10.1136/Acupmed-2016-011056 |
0.422 |
|
| 2016 |
Narayan HK, French B, Khan AM, Plappert T, Hyman D, Bajulaiye A, Domchek S, DeMichele A, Clark A, Matro J, Bradbury A, Fox K, Carver JR, Ky B. Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction. Jacc. Cardiovascular Imaging. PMID 27085442 DOI: 10.1016/J.Jcmg.2015.11.024 |
0.319 |
|
| 2016 |
Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. The Lancet. Oncology. PMID 26947331 DOI: 10.1016/S1470-2045(15)00613-0 |
0.573 |
|
| 2016 |
Sansone P, Ceccarelli C, Berishaj M, Chang Q, Rajasekhar VK, Perna F, Bowman RL, Vidone M, Daly L, Nnoli J, Santini D, Taffurelli M, Shih NN, Feldman M, Mao JJ, ... ... DeMichele A, et al. Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nature Communications. 7: 10442. PMID 26858125 DOI: 10.1038/Ncomms10442 |
0.394 |
|
| 2016 |
DeMichele A, Yee D, Paoloni M, Berry D, Esserman LJ. Neoadjuvant as Future for Drug Development in Breast Cancer--Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 22: 269. PMID 26728411 DOI: 10.1158/1078-0432.Ccr-15-1643 |
0.46 |
|
| 2016 |
Esserman L, Benz C, Demichele A. Targeting Molecular Aberrations in Breast Cancer: Is It about Time? American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 186-91. PMID 24451732 DOI: 10.14694/EdBook_AM.2012.32.186 |
0.469 |
|
| 2016 |
Palmer SC, Demichele A, Schapira M, Glanz K, Blauch AN, Pucci DA, Jacobs LA. Symptoms, unmet need, and quality of life among recent breast cancer survivors Journal of Community and Supportive Oncology. 14: 299-306. DOI: 10.12788/Jcso.0236 |
0.455 |
|
| 2016 |
Palmer SC, DeMichele A, Schapira MM, Glanz K, Blauch A, Pucci DA, Jacobs LA. Association of anxiety and depressive symptoms with differing needs among recent breast cancer (BC) survivors. Journal of Clinical Oncology. 34: 244-244. DOI: 10.1200/Jco.2016.34.3_Suppl.244 |
0.327 |
|
| 2016 |
Palmer SC, DeMichele A, Schapira MM, Glanz K, Blauch A, Pucci DA, Jacobs LA. Patient-reported outcomes (PROs), unmet need, and psychosocial adaptation among recent breast cancer (BC) survivors. Journal of Clinical Oncology. 34: 212-212. DOI: 10.1200/Jco.2016.34.3_Suppl.212 |
0.34 |
|
| 2016 |
SCHMITZ KH, DeMichele A, Dean LT, Troxel AB, Sarwer DB. WISER survivor: Exercise and/or weight loss in breast cancer survivors. Journal of Clinical Oncology. 34: TPS10140-TPS10140. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps10140 |
0.432 |
|
| 2016 |
Meric-Bernstam F, Tannir NM, Mier JW, DeMichele A, Telli ML, Fan AC, Munster PN, Carvajal RD, Orford KW, Bennett MK, Iliopoulos O, Owonikoko TK, Patel MR, McKay R, Infante JR, et al. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC). Journal of Clinical Oncology. 34: 4568-4568. DOI: 10.1200/Jco.2016.34.15_Suppl.4568 |
0.372 |
|
| 2016 |
Niu H, Shin H, Gao F, Zhang J, Bahamon B, Danaee H, Melichar B, Schilder RJ, Coleman RL, Adenis A, Behbakht K, DeMichele A, Dees EC, Perez K, Matulonis UA, et al. Correlation of an Aurora A single nucleotide polymorphism (SNP) with clinical responses to alisertib in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 34: 2583-2583. DOI: 10.1200/Jco.2016.34.15_Suppl.2583 |
0.345 |
|
| 2016 |
DeMichele A, Harding JJ, Telli ML, Munster PN, McKay R, Iliopoulos O, Orford KW, Bennett MK, Mier JW, Owonikoko TK, Patel MR, Carvajal RD, Meric-Bernstam F, Infante JR. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC). Journal of Clinical Oncology. 34: 1011-1011. DOI: 10.1200/Jco.2016.34.15_Suppl.1011 |
0.428 |
|
| 2016 |
Lynch M, Mankoff D, Bradbury A, Domchek S, Glick J, Matro J, DeMichele A, Clark A. Abstract P6-01-02: Flourine-18-fluorodeoxyglucose positron emission tomography for the evaluation of response to therapy in bone-dominant metastatic breast cancer: Examination in patients enrolled on UPCC 17113 Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P6-01-02 |
0.443 |
|
| 2016 |
Verma S, DeMichele A, Loi S, Ro J, Colleoni M, Iwata H, Harbeck N, Stearns V, Cristofanilli M, Bartlett CH, Schnell P, Zhang K, Thiele A, Turner N, Rugo H. Abstract P4-13-03: Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P4-13-03 |
0.391 |
|
| 2016 |
Cristofanilli M, Bondarenko I, Ro J, Im S, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Bartlett CH, Zhang K, Theall KP, Turner N, Slamon D. Abstract P4-13-01: PALOMA3: Phase 3 trial of fulvestrant with or without palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy—confirmed efficacy and safety Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P4-13-01 |
0.474 |
|
| 2016 |
Sansone P, Claudio C, Berishaj M, Chang Q, Vinagolu R, Perna F, Bowman R, Vidone M, Daly L, Nnoli J, Santini D, Mario T, Shih N, Feldman M, Mao JJ, ... ... DeMichele A, et al. Abstract LB-236: Self-renewal of CD133hi cells by IL6/Notch3 signaling regulates endocrine resistance in metastatic breast cancers Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-236 |
0.415 |
|
| 2016 |
Loibl S, Demichele A, Turner NM, Cristofanilli M, Loi S, Verma S, Bhattacharyya H, Ke Z, Giorgetti C, Bartlett CH, Iyer S, Colleoni M, Masuda N, Im S-, Harbeck N. Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR + , HER2- metastatic breast cancer Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw365.39 |
0.513 |
|
| 2016 |
Meric-Bernstam F, Tannir N, Harding J, Voss M, Mier J, DeMichele A, Munster P, Patel M, Iliopoulos O, Owonikoko T, Whiting S, Orford K, Bennett M, Carvajal R, McKay R, et al. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC) European Journal of Cancer. 69. DOI: 10.1016/S0959-8049(16)32626-0 |
0.335 |
|
| 2015 |
Datta J, Fracol M, McMillan MT, Berk E, Xu S, Goodman N, Lewis DA, DeMichele A, Czerniecki BJ. Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune Monitoring. Jama Oncology. 1-5. PMID 26719971 DOI: 10.1001/Jamaoncol.2015.5482 |
0.406 |
|
| 2015 |
Clark AS, Karasic TB, DeMichele A, Vaughn DJ, O'Hara M, Perini R, Zhang P, Lal P, Feldman M, Gallagher M, O'Dwyer PJ. Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development. Jama Oncology. 1-8. PMID 26633733 DOI: 10.1001/Jamaoncol.2015.4701 |
0.493 |
|
| 2015 |
Dean LT, DeMichele A, LeBlanc M, Stephens-Shields A, Li SQ, Colameco C, Coursey M, Mao JJ. Black breast cancer survivors experience greater upper extremity disability. Breast Cancer Research and Treatment. 154: 117-25. PMID 26420404 DOI: 10.1007/S10549-015-3580-3 |
0.463 |
|
| 2015 |
Mao JJ, Bowman MA, Xie SX, Bruner D, DeMichele A, Farrar JT. Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26304905 DOI: 10.1200/Jco.2015.60.9412 |
0.539 |
|
| 2015 |
DeMichele A, Chodosh LA. "Braking" the Cycle of Resistance in Endocrine Therapy for Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 4999-5001. PMID 26202949 DOI: 10.1158/1078-0432.Ccr-15-1146 |
0.449 |
|
| 2015 |
Brier MJ, Chambless D, Gross R, Su HI, DeMichele A, Mao JJ. Association between self-report adherence measures and oestrogen suppression among breast cancer survivors on aromatase inhibitors. European Journal of Cancer (Oxford, England : 1990). 51: 1890-6. PMID 26169018 DOI: 10.1016/J.Ejca.2015.06.113 |
0.42 |
|
| 2015 |
Bauml J, Chen L, Chen J, Boyer J, Kalos M, Li SQ, DeMichele A, Mao JJ. Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia? Breast Cancer Research : Bcr. 17: 89. PMID 26126656 DOI: 10.1186/S13058-015-0599-7 |
0.336 |
|
| 2015 |
Ashraf A, Gaonkar B, Mies C, DeMichele A, Rosen M, Davatzikos C, Kontos D. Breast DCE-MRI Kinetic Heterogeneity Tumor Markers: Preliminary Associations With Neoadjuvant Chemotherapy Response. Translational Oncology. 8: 154-62. PMID 26055172 DOI: 10.1016/J.Tranon.2015.03.005 |
0.409 |
|
| 2015 |
Chung SH, Feldman MD, Martinez D, Kim H, Putt ME, Busch DR, Tchou J, Czerniecki BJ, Schnall MD, Rosen MA, DeMichele A, Yodh AG, Choe R. Macroscopic optical physiological parameters correlate with microscopic proliferation and vessel area breast cancer signatures. Breast Cancer Research : Bcr. 17: 72. PMID 26013572 DOI: 10.1186/S13058-015-0578-Z |
0.436 |
|
| 2015 |
Datta J, Berk E, Xu S, Fitzpatrick E, Rosemblit C, Lowenfeld L, Goodman N, Lewis DA, Zhang PJ, Fisher C, Roses RE, DeMichele A, Czerniecki BJ. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer. Breast Cancer Research : Bcr. 17: 71. PMID 25997452 DOI: 10.1186/S13058-015-0584-1 |
0.428 |
|
| 2015 |
White J, DeMichele A. Neoadjuvant therapy for breast cancer: controversies in clinical trial design and standard of care. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 35: e17-23. PMID 25993169 DOI: 10.14694/EdBook_AM.2015.35.e17 |
0.39 |
|
| 2015 |
Tan AS, Nagler RH, Hornik RC, DeMichele A. Evolving Information Needs among Colon, Breast, and Prostate Cancer Survivors: Results from a Longitudinal Mixed-Effects Analysis. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 24: 1071-8. PMID 25979968 DOI: 10.1158/1055-9965.Epi-15-0041 |
0.459 |
|
| 2015 |
Melichar B, Adenis A, Lockhart AC, Bennouna J, Dees EC, Kayaleh O, Obermannova R, DeMichele A, Zatloukal P, Zhang B, Ullmann CD, Schusterbauer C. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. The Lancet. Oncology. 16: 395-405. PMID 25728526 DOI: 10.1016/S1470-2045(15)70051-3 |
0.482 |
|
| 2015 |
DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, et al. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2911-5. PMID 25712686 DOI: 10.1158/1078-0432.Ccr-14-1760 |
0.436 |
|
| 2015 |
DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, Lewis D, Langer M, Goodman N, Domchek S, Gogineni K, et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 995-1001. PMID 25501126 DOI: 10.1158/1078-0432.Ccr-14-2258 |
0.483 |
|
| 2015 |
Ou Y, Weinstein SP, Conant EF, Englander S, Da X, Gaonkar B, Hsieh MK, Rosen M, DeMichele A, Davatzikos C, Kontos D. Deformable registration for quantifying longitudinal tumor changes during neoadjuvant chemotherapy. Magnetic Resonance in Medicine. 73: 2343-56. PMID 25046843 DOI: 10.1002/Mrm.25368 |
0.348 |
|
| 2015 |
O'Hara MH, Edmonds C, Farwell M, Perini RF, Pryma DA, Teitelbaum UR, Giantonio BJ, Damjanov N, Lal P, Feldman MD, Zhang PJ, Mankoff DA, Gallagher M, DeMichele A, Vaughn DJ, et al. Phase II pharmacodynamic trial of palbociclib in patients with KRAS mutant colorectal cancer. Journal of Clinical Oncology. 33: 626-626. DOI: 10.1200/Jco.2015.33.3_Suppl.626 |
0.35 |
|
| 2015 |
Vonderheide RH, Aggarwal C, Bajor DL, Goldenberg J, Loch C, Lee JC, Yan J, Morrow MP, DeMichele A, Langer CJ, O'Dwyer PJ, Weiner DB, Yang Z, Bagarazzi ML. Study of hTERT and IL-12 DNA immunotherapy using electroporation in patients with solid tumors after definitive surgery and adjuvant therapy. Journal of Clinical Oncology. 33: TPS3104-TPS3104. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps3104 |
0.318 |
|
| 2015 |
Dean LT, DeMichele A, Li SQ, Colameco C, Stephens-Shields AJ, Coursey M, Mao JJ. Racial differences in upper extremity function for breast cancer survivors. Journal of Clinical Oncology. 33: 9569-9569. DOI: 10.1200/Jco.2015.33.15_Suppl.9569 |
0.544 |
|
| 2015 |
Maxwell KN, Wenz B, Wubbenhorst B, D'Andrea KP, Garman B, Weathers B, Goodman N, Colameco C, Long JM, Powers J, Stopfer J, Bradbury AR, DeMichele A, Domchek SM, Nathanson KL. Characteristics of high risk breast cancer patients with mutations identified by multiplex panel testing. Journal of Clinical Oncology. 33: 1511-1511. DOI: 10.1200/Jco.2015.33.15_Suppl.1511 |
0.51 |
|
| 2015 |
Mao JJ, Xie SX, Bowman MA, Bruner D, Li SQ, DeMichele A, Farrar JT. Abstract PD4-7: A randomized placebo-controlled trial of acupuncture and gabapentin for hot flashes among breast cancer survivors Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd4-7 |
0.486 |
|
| 2015 |
Brier MJ, Chambless DL, Lee L, DeMichele A, Mao JJ. Abstract P5-17-01: Development and validation of the Penn arthralgia aging scale among breast cancer survivors on aromatase inhibitors Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P5-17-01 |
0.402 |
|
| 2015 |
Yau C, Wolf D, Sanil A, Veer Lv', Petricoin EF, Buxton M, Gray J, DeMichele A, Hogarth M, Hylton N, Perlmutter J, Paoloni M, Symmans F, Yee D, Berry D, et al. Abstract P3-06-37: I-SPY 2 qualifying biomarker evaluation (QBE): The challenge and opportunity for interrogating predicted pathways in an adaptive design biomarker rich trial Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-37 |
0.4 |
|
| 2015 |
Yau C, Wolf DM, Sanil A, Chien J, Wallace A, Boughey J, Yee D, Tripathy D, DeMichele A, Nanda R, Chiu S, Isaacs C, Albain K, Kaplan H, Moulder S, et al. Abstract P3-06-29: MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-29 |
0.467 |
|
| 2015 |
Wolf DM, Yau C, Sanil A, Chien J, Wallace A, DeMichele A, Kaplan H, Yee D, Isaacs C, Albain K, Viscuzi R, Boughey J, Moulder S, Chui S, Khan Q, et al. Abstract P3-06-25: MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-25 |
0.442 |
|
| 2015 |
Wulfkuhle JD, Yau C, Wolf DM, Gallagher RI, Sanil A, Brown-Swigart L, Flynn S, Hirst G, Investigators IT, Buxton M, DeMichele A, Hylton N, Symmans WF, Veer Lv, Yee D, et al. Abstract P3-06-15: Evaluation of HER family protein signaling network as a predictive biomarker for pCR for breast cancer patients treated with neratinib in the I-SPY 2 trial Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-15 |
0.397 |
|
| 2015 |
Wolf DM, Yau C, Sanil A, Daemen A, Heiser L, Gray J, Brown-Swigart L, Flynn S, Hirst G, Investigators IT, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, et al. Abstract P3-06-05: Evaluation of anin vitroderived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL: Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-05 |
0.484 |
|
| 2015 |
Wenz B, Maxwell KN, Wubbenhorst B, D'Andrea K, Garman B, Long JM, Powers J, Stopfer JE, Bradbury AR, DeMichele A, Domchek SM, Nathanson KL. Abstract 4663: Identification of germline variants in cancer susceptibility genes in patients with multiple primary cancers Cancer Research. 75: 4663-4663. DOI: 10.1158/1538-7445.Am2015-4663 |
0.495 |
|
| 2015 |
Datta J, Berk E, Xu S, Fitzpatrick E, Lowenfeld L, Goodman N, Lewis D, Roses RE, DeMichele A, Czerniecki BJ. Abstract 1308: Depressed anti-HER2 CD4 Th1 responses correlate with residual disease following neoadjuvant therapy in HER2+ breast cancer patients and can be restored by dendritic cell vaccination Cancer Research. 75: 1308-1308. DOI: 10.1158/1538-7445.Am2015-1308 |
0.419 |
|
| 2015 |
Meric-Bernstam F, DeMichele A, Telli ML, Munster P, Orford KW, Demitri GD, Schwartz GK, Iliopoulos O, Mier JW, Owonikoko TK, Bennett MK, Patel MR, Infante JR, Harding JJ. Abstract C49: Phase 1 study of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase in patients with refractory solid tumors Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C49 |
0.382 |
|
| 2015 |
Wu J, Ou Y, Weinstein SP, Conant EF, Yu N, Hoshmand V, Keller B, Ashraf AB, Rosen M, Demichele A, Davatzikos C, Kontos D. Quantification of tumor changes during neoadjuvant chemotherapy with longitudinal breast DCE-MRI registration Progress in Biomedical Optics and Imaging - Proceedings of Spie. 9414. DOI: 10.1117/12.2081938 |
0.375 |
|
| 2015 |
Homer MV, Charo LM, Natarajan L, Haunschild C, DeMichele A, Su I. Predicting menopause in breast cancer survivors: an analysis of 13 single nucleotide polymorphisms Fertility and Sterility. 104. DOI: 10.1016/J.Fertnstert.2015.07.328 |
0.49 |
|
| 2015 |
Charo LM, Homer MV, Natarajan L, Haunschild C, DeMichele A, Su I. Drug metabolizing enzme polymorphisms are associated with chemotherapy related amenorrhea in young breast cancer survivors Fertility and Sterility. 104. DOI: 10.1016/J.Fertnstert.2015.07.012 |
0.479 |
|
| 2015 |
Clark AS, DeMichele A. The Cyclin D/Cyclin-dependent Kinase 4/6 Complex as a Target in the Treatment of Breast Cancer Current Breast Cancer Reports. 7: 175-182. DOI: 10.1007/S12609-015-0189-9 |
0.498 |
|
| 2014 |
Beidas RS, Paciotti B, Barg F, Branas AR, Brown JC, Glanz K, DeMichele A, DiGiovanni L, Salvatore D, Schmitz KH. A hybrid effectiveness-implementation trial of an evidence-based exercise intervention for breast cancer survivors. Journal of the National Cancer Institute. Monographs. 2014: 338-45. PMID 25749601 DOI: 10.1093/Jncimonographs/Lgu033 |
0.481 |
|
| 2014 |
Maxwell KN, Wubbenhorst B, D'Andrea K, Garman B, Long JM, Powers J, Rathbun K, Stopfer JE, Zhu J, Bradbury AR, Simon MS, DeMichele A, Domchek SM, Nathanson KL. Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 25503501 DOI: 10.1038/Gim.2014.176 |
0.525 |
|
| 2014 |
Su HCI, Haunschild C, Chung K, Komrokian S, Boles S, Sammel MD, DeMichele A. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients Cancer. 120: 3691-3698. PMID 25081546 DOI: 10.1002/Cncr.28942 |
0.475 |
|
| 2014 |
Mao JJ, Farrar JT, Bruner D, Zee J, Bowman M, Seluzicki C, DeMichele A, Xie SX. Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial. Cancer. 120: 3744-51. PMID 25077452 DOI: 10.1002/Cncr.28917 |
0.44 |
|
| 2014 |
Garland SN, Johnson B, Palmer C, Speck RM, Donelson M, Xie SX, DeMichele A, Mao JJ. Physical activity and telomere length in early stage breast cancer survivors. Breast Cancer Research : Bcr. 16: 413. PMID 25074648 DOI: 10.1186/S13058-014-0413-Y |
0.426 |
|
| 2014 |
Choe R, Putt ME, Carlile PM, Durduran T, Giammarco JM, Busch DR, Jung KW, Czerniecki BJ, Tchou J, Feldman MD, Mies C, Rosen MA, Schnall MD, DeMichele A, Yodh AG. Optically measured microvascular blood flow contrast of malignant breast tumors. Plos One. 9: e99683. PMID 24967878 DOI: 10.1371/Journal.Pone.0099683 |
0.418 |
|
| 2014 |
Clark AS, Chen J, Kapoor S, Friedman C, Mies C, Esserman L, DeMichele A. Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657). Cancer Medicine. 3: 693-701. PMID 24719175 DOI: 10.1002/Cam4.235 |
0.475 |
|
| 2014 |
Palmer SC, Jacobs LA, DeMichele A, Risendal B, Jones AF, Stricker CT. Metrics to evaluate treatment summaries and survivorship care plans: a scorecard. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 22: 1475-83. PMID 24414997 DOI: 10.1007/S00520-013-2107-X |
0.443 |
|
| 2014 |
Mao JJ, Xie SX, Farrar JT, Stricker CT, Bowman MA, Bruner D, DeMichele A. A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use. European Journal of Cancer (Oxford, England : 1990). 50: 267-76. PMID 24210070 DOI: 10.1016/J.Ejca.2013.09.022 |
0.497 |
|
| 2014 |
LeBlanc M, Stineman M, DeMichele A, Stricker C, Mao JJ. Validation of QuickDASH outcome measure in breast cancer survivors for upper extremity disability. Archives of Physical Medicine and Rehabilitation. 95: 493-8. PMID 24095658 DOI: 10.1016/J.Apmr.2013.09.016 |
0.446 |
|
| 2014 |
Buxton MB, Natsuhara K, DeMichele A, Perlmutter J, Hylton NM, Yee D, Veer Lv, Symmans WF, Hogarth M, Lyandres J, Davis SE, Flynn S, Paoloni M, Berry DA, Esserman L. Transforming the clinical trial process: The I-SPY 2 trial as a model for improving the efficiency of clinical trials and accelerating the drug-screening process. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps2633 |
0.419 |
|
| 2014 |
Clark AS, O'Dwyer PJ, Heitjan D, Lal P, Feldman MD, Gallagher M, Redlinger C, Colameco C, Lewis D, Zafman K, Langer M, Rosen MA, Gogineni K, Bradbury AR, Domchek SM, ... ... DeMichele A, et al. A phase I trial of palbociclib and paclitaxel in metastatic breast cancer. Journal of Clinical Oncology. 32: 527-527. DOI: 10.1200/Jco.2014.32.15_Suppl.527 |
0.549 |
|
| 2014 |
DeMichele A, Dickson MA, Clark AS, Colameco C, Gallagher M, Gramlich K, Zafman K, Lewis D, Langer M, Vaughn DJ, Schwartz GK, O'Dwyer PJ. Characterization of isolated, uncomplicated neutropenia–related to the CDK4/6 inhibitor palbociclib. Journal of Clinical Oncology. 32: 2547-2547. DOI: 10.1200/Jco.2014.32.15_Suppl.2547 |
0.358 |
|
| 2014 |
Maxwell KN, Wubbenhorst B, Garman B, D'Andrea KP, Rathbun K, Long J, Powers J, Stopfer J, Bradbury AR, DeMichele A, Domchek SM, Nathanson KL. Prevalence of mutations in a panel of breast cancer susceptibility genes in patients with early onset breast cancer. Journal of Clinical Oncology. 32: 1510-1510. DOI: 10.1200/Jco.2014.32.15_Suppl.1510 |
0.511 |
|
| 2014 |
Park JW, Liu MC, Yee D, DeMichele A, Veer Lv', Hylton N, Symmans F, Buxton MB, Chien AJ, Wallace A, Melisko M, Schwab R, Boughey J, Tripathy D, Kaplan H, et al. Abstract CT227: Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct227 |
0.496 |
|
| 2014 |
Esserman LJ, DeMichele A. Accelerated approval for pertuzumab in the neoadjuvant setting: Winds of change? Clinical Cancer Research. 20: 3632-3636. DOI: 10.1158/1078-0432.Ccr-13-3131 |
0.41 |
|
| 2013 |
Chim K, Xie SX, Stricker CT, Li QS, Gross R, Farrar JT, DeMichele A, Mao JJ. Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. Bmc Cancer. 13: 401. PMID 24004677 DOI: 10.1186/1471-2407-13-401 |
0.465 |
|
| 2013 |
Speck RM, Sammel MD, Farrar JT, Hennessy S, Mao JJ, Stineman MG, DeMichele A. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. Journal of Oncology Practice / American Society of Clinical Oncology. 9: e234-40. PMID 23943894 DOI: 10.1200/Jop.2012.000863 |
0.46 |
|
| 2013 |
Alvarez JV, Pan Tc, Ruth J, Feng Y, Zhou A, Pant D, Grimley JS, Wandless TJ, DeMichele A, Chodosh LA. Par-4 Downregulation Promotes Breast Cancer Recurrence by Preventing Multinucleation following Targeted Therapy Cancer Cell. 24: 30-44. PMID 23770012 DOI: 10.1016/J.Ccr.2013.05.007 |
0.502 |
|
| 2013 |
Gabriel CA, Mitra N, Demichele A, Rebbeck T. Association of progesterone receptor gene (PGR) variants and breast cancer risk in African American women. Breast Cancer Research and Treatment. 139: 833-43. PMID 23764995 DOI: 10.1007/S10549-013-2592-0 |
0.512 |
|
| 2013 |
Rastogi P, Geyer CE, Mamounas EP, DeMichele A. Drug development: neoadjuvant opportunities in breast cancer. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 73-9. PMID 23714461 DOI: 10.1200/EdBook_AM.2013.33.73 |
0.404 |
|
| 2013 |
DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, et al. Developing safety criteria for introducing new agents into neoadjuvant trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2817-23. PMID 23470967 DOI: 10.1158/1078-0432.Ccr-12-2620 |
0.346 |
|
| 2013 |
Busch DR, Choe R, Rosen MA, Guo W, Durduran T, Feldman MD, Mies C, Czerniecki BJ, Tchou J, Demichele A, Schnall MD, Yodh AG. Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy. Biomedical Optics Express. 4: 105-21. PMID 23304651 DOI: 10.1364/Boe.4.000105 |
0.502 |
|
| 2013 |
Su HI, Flatt SW, Natarajan L, Demichele A, Steiner AZ. Impact of breast cancer on anti-mullerian hormone levels in young women Breast Cancer Research and Treatment. 137: 571-577. PMID 23224236 DOI: 10.1007/S10549-012-2361-5 |
0.547 |
|
| 2013 |
Chen F, Chen GK, Stram DO, Millikan RC, Ambrosone CB, John EM, Bernstein L, Zheng W, Palmer JR, Hu JJ, Rebbeck TR, Ziegler RG, Nyante S, Bandera EV, Ingles SA, ... ... Demichele A, et al. A genome-wide association study of breast cancer in women of African ancestry. Human Genetics. 132: 39-48. PMID 22923054 DOI: 10.1007/S00439-012-1214-Y |
0.442 |
|
| 2013 |
Speck RM, DeMichele A, Farrar JT, Hennessy S, Mao JJ, Stineman MG, Barg FK. Taste alteration in breast cancer patients treated with taxane chemotherapy: experience, effect, and coping strategies. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 21: 549-55. PMID 22864536 DOI: 10.1007/S00520-012-1551-3 |
0.537 |
|
| 2013 |
Desai K, Mao JJ, Su I, Demichele A, Li Q, Xie SX, Gehrman PR. Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors Supportive Care in Cancer. 21: 43-51. PMID 22584732 DOI: 10.1007/S00520-012-1490-Z |
0.477 |
|
| 2013 |
Mao JJ, Xie S, Farrar JT, Stricker CT, Bowman M, Bruner D, DeMichele A. Electro-acupuncture for joint pain related to aromatase inhibitors among breast cancer survivors: A randomized placebo-controlled trial. Journal of Clinical Oncology. 31: 9639-9639. DOI: 10.1200/Jco.2013.31.15_Suppl.9639 |
0.455 |
|
| 2013 |
Speck RM, Farrar JT, Sammel MD, Mao JJ, Stineman MG, Hennessy S, DeMichele A. Risk for dose-limiting chemotherapy-induced peripheral neuropathy in black women with breast cancer. Journal of Clinical Oncology. 31: 6560-6560. DOI: 10.1200/Jco.2013.31.15_Suppl.6560 |
0.395 |
|
| 2013 |
DeMichele A, Clark AS, Heitjan D, Randolph S, Gallagher M, Lal P, Feldman MD, Zhang PJ, Schnader A, Zafman K, Domchek SM, Gogineni K, Keefe SM, Fox KR, O'Dwyer PJ. A phase II trial of an oral CDK 4/6 inhibitor, PD0332991, in advanced breast cancer. Journal of Clinical Oncology. 31: 519-519. DOI: 10.1200/Jco.2013.31.15_Suppl.519 |
0.424 |
|
| 2013 |
Melichar B, DeMichele A, Adenis A, Bourbouloux E, Tan-Chiu E, Niu H, Schusterbauer C, Ullmann CD, Zhang B, Benaim E. Abstract PD5-5: Phase 2 study of single agent MLN8237 (alisertib), an investigational aurora A kinase (AAK) inhibitor, in patients (pts) with relapsed/refractory breast cancer (BrC) Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Pd5-5 |
0.389 |
|
| 2013 |
Haunschild C, Sammel M, Chung K, DeMichele A, Su H. Pre-chemotherapy levels of follicle stimulating hormone and anti-mullerian hormone predict time to return of ovarian function in young breast cancer patients Fertility and Sterility. 100: S44. DOI: 10.1016/J.Fertnstert.2013.07.1814 |
0.47 |
|
| 2013 |
Su HI, Flatt SW, Natarajan L, DeMichele A, Steiner AZ. Erratum to: Impact of breast cancer on anti-mullerian hormone levels in young women Breast Cancer Research and Treatment. 138: 975-975. DOI: 10.1007/S10549-013-2492-3 |
0.482 |
|
| 2012 |
Wulfkuhle JD, Berg D, Wolff C, Langer R, Tran K, Illi J, Espina V, Pierobon M, Deng J, DeMichele A, Walch A, Bronger H, Becker I, Waldhör C, Höfler H, et al. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6426-35. PMID 23045247 DOI: 10.1158/1078-0432.Ccr-12-0452 |
0.408 |
|
| 2012 |
Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3242-9. PMID 22649152 DOI: 10.1200/Jco.2011.39.2779 |
0.483 |
|
| 2012 |
Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ, Colligon TA, Trosko JA, Leinbach LI, Pletcher CH, Tweed CK, DeMichele A, Fox KR, Domchek SM, Riley JL, et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Science Translational Medicine. 4: 134ra62. PMID 22593175 DOI: 10.1126/Scitranslmed.3003330 |
0.348 |
|
| 2012 |
Gogineni K, DeMichele A. Current approaches to the management of Her2-negative metastatic breast cancer Breast Cancer Research. 14. PMID 22429313 DOI: 10.1186/Bcr3064 |
0.517 |
|
| 2012 |
Friedman CF, DeMichele A, Su HI, Feng R, Kapoor S, Desai K, Mao JJ. Vitamin d deficiency in postmenopausal breast cancer survivors. Journal of Women's Health (2002). 21: 456-62. PMID 22385131 DOI: 10.1089/Jwh.2011.3009 |
0.363 |
|
| 2012 |
Speck RM, DeMichele A, Farrar JT, Hennessy S, Mao JJ, Stineman MG, Barg FK. Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 20: 2433-9. PMID 22231480 DOI: 10.1007/S00520-011-1365-8 |
0.449 |
|
| 2012 |
Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Research and Treatment. 132: 1049-62. PMID 22198468 DOI: 10.1007/S10549-011-1895-2 |
0.487 |
|
| 2012 |
Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS, Shaik MN, Wilner KD, O'Dwyer PJ, Schwartz GK. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 568-76. PMID 22090362 DOI: 10.1158/1078-0432.Ccr-11-0509 |
0.305 |
|
| 2012 |
Hirsh RL, Demichele A. The role of lapatinib in the preoperative therapy of breast cancer Current Oncology Reports. 14: 44-47. PMID 22037924 DOI: 10.1007/S11912-011-0206-8 |
0.551 |
|
| 2012 |
Palmer SC, Taggi A, Demichele A, Coyne JC. Is screening effective in detecting untreated psychiatric disorders among newly diagnosed breast cancer patients? Cancer. 118: 2735-43. PMID 21989608 DOI: 10.1002/Cncr.26603 |
0.359 |
|
| 2012 |
Galantino ML, Desai K, Greene L, Demichele A, Stricker CT, Mao JJ. Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor-associated arthralgias. Integrative Cancer Therapies. 11: 313-20. PMID 21733988 DOI: 10.1177/1534735411413270 |
0.432 |
|
| 2012 |
Clark AS, DeMichele A. Vitamin D and breast cancer: evidence for biological and clinical significance Breast Cancer Management. 1: 143-155. DOI: 10.2217/Bmt.12.28 |
0.465 |
|
| 2012 |
Choe R, Durduran T, Busch DR, Chung SH, Pathak S, Ban HY, Foster EK, Averna TA, Buckley EM, Kim MN, Mies C, Rosen MA, Schnall MD, DeMichele A, Yodh AG. Early changes in breast cancer blood flow due to chemotherapy: Potential predictor for therapeutic efficacy Biomedical Optics, Biomed 2012. BW3A.5. DOI: 10.1364/Biomed.2012.Bw3A.5 |
0.477 |
|
| 2012 |
Busch DR, Guo W, Choe R, Durduran T, Feldman MD, Mies C, Czerniecki BJ, Tchou J, DeMichele A, Rosen MA, Schnall MD, Yodh AG. Computer Aided Monitoring of Neoadjuvant Chemotherapy for Breast Cancer Ieee Transactions On Biomedical Engineering. DOI: 10.1364/Biomed.2012.Bsu5A.7 |
0.451 |
|
| 2012 |
Speck RM, DeMichele A, Farrar JT, Hennessy S, Mao J, Stineman MG, Barg FK. Coping with the burden of taste alteration, a toxicity of taxane-based chemotherapy. Journal of Clinical Oncology. 30: e19531-e19531. DOI: 10.1200/Jco.2012.30.15_Suppl.E19531 |
0.401 |
|
| 2012 |
Alvarez R, DeMichele A, Mailliez A, Benaim E, Fingert H, Schusterbauer C, Zhang B, Melichar B. Abstract P6-10-02: MLN8237 (alisertib), an investigational Aurora A Kinase inhibitor, in patients with breast cancer: Emerging phase 2 results Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P6-10-02 |
0.476 |
|
| 2012 |
DeMichele A. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer Breast Diseases. 23: 246-248. DOI: 10.1016/j.breastdis.2012.07.003 |
0.397 |
|
| 2012 |
Busch DR, Guo W, Choe R, Durduran T, Feldman MD, Mies C, Czerniecki BJ, Tchou J, DeMichele A, Rosen MA, Schnall MD, Yodh AG. Computer aided monitoring of neoadjuvant chemotherapy for breast cancer Biomedical Optics, Biomed 2012. BSu5A.7. |
0.319 |
|
| 2011 |
Perini RF, DeMichele A, Vaughn DJ, Gallagher M, Sun W, Giantonio BJ, Teitelbaum UR, Randolph S, Christensen JG, Courtney RD, Pryma DA, Divgi CR, O'Dwyer PJ. Phase II/pharmacodynamic trial of PD0332991 in patients with breast, colon, germ cell, and epithelial tumors containing amplification of CCND1. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3088. PMID 28022524 DOI: 10.1200/Jco.2011.29.15_Suppl.3088 |
0.446 |
|
| 2011 |
Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, ... ... DeMichele A, et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. Jama. 305: 1873-81. PMID 21558518 DOI: 10.1001/Jama.2011.593 |
0.356 |
|
| 2011 |
Mao JJ, Su HI, Feng R, Donelson ML, Aplenc R, Rebbeck TR, Stanczyk F, DeMichele A. Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Research : Bcr. 13: R8. PMID 21251330 DOI: 10.1186/Bcr2813 |
0.453 |
|
| 2011 |
Su HI, Chung K, Sammel MD, Gracia CR, DeMichele A. Antral follicle count provides additive information to hormone measures for determining ovarian function in breast cancer survivors. Fertility and Sterility. 95: 1857-9. PMID 21193192 DOI: 10.1016/J.Fertnstert.2010.12.005 |
0.501 |
|
| 2011 |
Rhee SS, Lim B, Kim H, Wang Y, Aziz U, Butt U, Tang W, Vuchak LA, DeMichele A, Troxel AB, Feldman MD, Meinkoth JL, Brose MS. Abstract 3840: Rap1 GTPase activating protein (Rap1GAP) is downregulated in DCIS and invasive ductal carcinoma Cancer Research. 71: 3840-3840. DOI: 10.1158/1538-7445.Am2011-3840 |
0.448 |
|
| 2011 |
Su HI, Komrokian S, DeMichele A, Stanczyk FZ, Steiner AZ. Anti-mullerian hormone in newly diagnosed breast cancer patients may be lower than in healthy women Fertility and Sterility. 96. DOI: 10.1016/J.Fertnstert.2011.07.300 |
0.508 |
|
| 2010 |
Desai K, Bowman MA, Galantino ML, Hughes-Halbert C, Vapiwala N, Demichele A, Mao JJ. Predictors of yoga use among patients with breast cancer Explore: the Journal of Science and Healing. 6: 359-363. PMID 21040884 DOI: 10.1016/J.Explore.2010.08.002 |
0.526 |
|
| 2010 |
Norman SA, Localio AR, Kallan MJ, Weber AL, Torpey HA, Potashnik SL, Miller LT, Fox KR, DeMichele A, Solin LJ. Risk factors for lymphedema after breast cancer treatment. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 19: 2734-46. PMID 20978176 DOI: 10.1158/1055-9965.Epi-09-1245 |
0.52 |
|
| 2010 |
Nagler RH, Gray SW, Romantan A, Kelly BJ, DeMichele A, Armstrong K, Schwartz JS, Hornik RC. Differences in information seeking among breast, prostate, and colorectal cancer patients: results from a population-based survey. Patient Education and Counseling. 81: S54-62. PMID 20934297 DOI: 10.1016/J.Pec.2010.09.010 |
0.422 |
|
| 2010 |
Abramson VG, Troxel AB, Feldman M, Mies C, Wang Y, Sherman L, McNally S, Diehl A, Demichele A. Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome. Anticancer Research. 30: 1279-85. PMID 20530440 |
0.312 |
|
| 2010 |
Gor PP, Su HI, Gray RJ, Gimotty PA, Horn M, Aplenc R, Vaughan WP, Tallman MS, Rebbeck TR, DeMichele A. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Research : Bcr. 12: R26. PMID 20459744 DOI: 10.1186/Bcr2570 |
0.482 |
|
| 2010 |
Busch DR, Guo W, Choe R, Durduran T, Feldman MD, Mies C, Rosen MA, Schnall MD, Czerniecki BJ, Tchou J, DeMichele A, Putt ME, Yodh AG. Computer aided automatic detection of malignant lesions in diffuse optical mammography. Medical Physics. 37: 1840-9. PMID 20443506 DOI: 10.1118/1.3314075 |
0.303 |
|
| 2010 |
Keefe SM, Demichele A. The expanding role of bevacizumab in the treatment of human epidermal growth factor receptor 2-negative breast cancer Current Oncology Reports. 12: 22-25. PMID 20425604 DOI: 10.1007/S11912-009-0080-9 |
0.441 |
|
| 2010 |
Su HI, Sammel MD, Springer E, Freeman EW, DeMichele A, Mao JJ. Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors. Breast Cancer Research and Treatment. 124: 205-11. PMID 20182796 DOI: 10.1158/0008-5472.Sabcs-09-1059 |
0.45 |
|
| 2010 |
Su HI, Sammel MD, Green J, Velders L, Stankiewicz C, Matro J, Freeman EW, Gracia CR, DeMichele A. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer. 116: 592-9. PMID 19918920 DOI: 10.1002/Cncr.24746 |
0.489 |
|
| 2010 |
Su HI, Sammel MD, Velders L, Horn M, Stankiewicz C, Matro J, Gracia CR, Green J, DeMichele A. Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. Fertility and Sterility. 94: 645-54. PMID 19376514 DOI: 10.1016/J.Fertnstert.2009.03.034 |
0.501 |
|
| 2010 |
Bonner Millar LP, Casarett D, Vapiwala N, DeMichele A, Stricker CT, Velders L, Mao JJ. Integrating Complementary Therapies into an Academic Cancer Center: The Perspective of Breast Cancer Patients Journal of the Society For Integrative Oncology. 8: 106-113. DOI: 10.2310/7200.2010.0004 |
0.45 |
|
| 2010 |
Choe R, Durduran T, Chung SH, Konecky SD, Pathak S, Ban HY, Busch DR, Buckley EM, Kim MN, DeMichele A, Mies C, Rosen MA, Schnall MD, Yodh AG. Breast Cancer Therapy Monitoring with Diffuse Optical Tomography and Diffuse Correlation Spectroscopy Ieee Transactions On Biomedical Engineering. DOI: 10.1364/Biomed.2010.Bsub2 |
0.392 |
|
| 2010 |
Friedman CF, Bruner D, Xie S, Desai K, Stricker CT, DeMichele A, Mao J. Functional disability and aromatase inhibitor-associated arthralgia in breast cancer survivors. Journal of Clinical Oncology. 28: 9156-9156. DOI: 10.1200/Jco.2010.28.15_Suppl.9156 |
0.526 |
|
| 2010 |
Stricker CT, Palmer SC, DeMichele A, Mao J. Understanding premature discontinuation of aromatase inhibitor (AI) therapy in postmenopausal breast cancer survivors. Journal of Clinical Oncology. 28: 6073-6073. DOI: 10.1200/Jco.2010.28.15_Suppl.6073 |
0.54 |
|
| 2010 |
Mao J, Su I, Feng R, Desai K, Horn M, Chan D, DeMichele A. Genetic variation in CYP19A1 and interleukin-6 and aromatase inhibitor-associated arthralgia in breast cancer survivors. Journal of Clinical Oncology. 28: 526-526. DOI: 10.1200/Jco.2010.28.15_Suppl.526 |
0.399 |
|
| 2010 |
Friedman C, DeMichele A, Su H, Feng R, Kapoor S, Desai K, Mao J. Abstract P2-14-11: Vitamin D Deficiency in Post-Menopausal Breast Cancer Survivors Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P2-14-11 |
0.362 |
|
| 2009 |
Lin C, Moore D, DeMichele A, Ollila D, Montgomery L, Liu M, Krontiras H, Gomez R, Esserman L. Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1503. PMID 27964313 DOI: 10.1200/Jco.2009.27.15_Suppl.1503 |
0.424 |
|
| 2009 |
Desai K, DeMichele A, Bruner D, Vapiwala N, Hughes Halbert C, Stricker C, Mao JJ. Factors associated with willingness to participate in an acupuncture clinical trial for arthralgia among breast cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6596. PMID 27963895 DOI: 10.1200/Jco.2009.27.15_Suppl.6596 |
0.549 |
|
| 2009 |
DeMichele A, Dunn L, Gimotty P, Livasy C, Perou C, Carey L, Esserman L. Loss of p27 expression and response to neoadjuvant chemotherapy: Results from the I-SPY Trial (CALGB150007/150012, ACRIN6657). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 11091. PMID 27963119 DOI: 10.1200/Jco.2009.27.15_Suppl.11091 |
0.451 |
|
| 2009 |
Jacobs LA, Palmer SC, Schwartz LA, DeMichele A, Mao JJ, Carver J, Gracia C, Hill-Kayser CE, Metz JM, Hampshire MK, Vachani C, Pucci D, Meadows AT. Adult cancer survivorship: evolution, research, and planning care. Ca: a Cancer Journal For Clinicians. 59: 391-410. PMID 19897841 DOI: 10.3322/Caac.20040 |
0.352 |
|
| 2009 |
Kim S, Hagemann A, Demichele A. Immuno-Modulatory Gene Polymorphisms and Outcome in Breast and Ovarian Cancer Immunological Investigations. 38: 324-340. PMID 19811442 DOI: 10.1080/08820130902910567 |
0.437 |
|
| 2009 |
Mao JJ, Bruner DW, Stricker C, Farrar JT, Xie SX, Bowman MA, Pucci D, Han X, DeMichele A. Feasibility trial of electroacupuncture for aromatase inhibitor--related arthralgia in breast cancer survivors. Integrative Cancer Therapies. 8: 123-9. PMID 19679620 DOI: 10.1177/1534735409332903 |
0.536 |
|
| 2009 |
Dunn L, DeMichele A. Genomic predictors of outcome and treatment response in breast cancer Molecular Diagnosis and Therapy. 13: 73-90. PMID 19537843 DOI: 10.1007/Bf03256317 |
0.479 |
|
| 2009 |
Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, Greene BT, DeMichele A. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer. 115: 3631-9. PMID 19517460 DOI: 10.1002/Cncr.24419 |
0.506 |
|
| 2009 |
DeMichele A, Fox KR. Optimizing outcomes with bevacizumab by better targeting patients and tumors Oncology. 23: 339-340. PMID 19476263 |
0.417 |
|
| 2009 |
DeMichele A, Gray R, Horn M, Chen J, Aplenc R, Vaughan WP, Tallman MS. Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. Cancer Research. 69: 4184-91. PMID 19435922 DOI: 10.1158/0008-5472.Can-08-2989 |
0.457 |
|
| 2009 |
Choe R, Konecky SD, Corlu A, Lee K, Durduran T, Busch DR, Pathak S, Czerniecki BJ, Tchou J, Fraker DL, Demichele A, Chance B, Arridge SR, Schweiger M, Culver JP, et al. Differentiation of benign and malignant breast tumors by in-vivo three-dimensional parallel-plate diffuse optical tomography. Journal of Biomedical Optics. 14: 024020. PMID 19405750 DOI: 10.1117/1.3103325 |
0.305 |
|
| 2009 |
Gray SW, Armstrong K, Demichele A, Schwartz JS, Hornik RC. Colon cancer patient information seeking and the adoption of targeted therapy for on-label and off-label indications. Cancer. 115: 1424-34. PMID 19235785 DOI: 10.1002/Cncr.24186 |
0.399 |
|
| 2009 |
Mao JJ, Bowman MA, Stricker CT, DeMichele A, Jacobs L, Chan D, Armstrong K. Delivery of survivorship care by primary care physicians: the perspective of breast cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 933-8. PMID 19139437 DOI: 10.1200/Jco.2008.18.0679 |
0.402 |
|
| 2009 |
Setiawan VW, Doherty JA, Shu XO, Akbari MR, Chen C, De Vivo I, Demichele A, Garcia-Closas M, Goodman MT, Haiman CA, Hankinson SE, Henderson BE, Horn-Ross PL, Lacey JV, Le Marchand L, et al. Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 18: 242-7. PMID 19124504 DOI: 10.1158/1055-9965.Epi-08-0689 |
0.352 |
|
| 2009 |
Norman SA, Localio AR, Potashnik SL, Simoes Torpey HA, Kallan MJ, Weber AL, Miller LT, Demichele A, Solin LJ. Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 390-7. PMID 19064976 DOI: 10.1200/Jco.2008.17.9291 |
0.478 |
|
| 2009 |
Rebbeck TR, DeMichele A, Tran TV, Panossian S, Bunin GR, Troxel AB, Strom BL. Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Carcinogenesis. 30: 269-74. PMID 19028704 DOI: 10.1093/Carcin/Bgn247 |
0.517 |
|
| 2009 |
Choe R, Konecky S, Corlu A, Lee K, Durduran T, Busch, Czerniecki B, Tchou J, Fraker D, DeMichele A, Chance B, Putt M, Schnall, Rosen M, Yodh A. Differentiation of benign and malignant breast lesions by in-vivo three-dimensional diffuse optical tomography. Cancer Research. 69: 805. DOI: 10.1158/0008-5472.Sabcs-805 |
0.374 |
|
| 2009 |
Mao J, Stricker C, Farrar J, Xie S, Bowman M, Bruner D, Pucci D, Han X, DeMichele A. Feasibility trial of electro-acupuncture for aromatase inhibitor related arthralgia in breast cancer survivors. Cancer Research. 69: 3105. DOI: 10.1158/0008-5472.Sabcs-3105 |
0.486 |
|
| 2009 |
Gomez R, Zakhireh J, Moore D, DeMichele A, Przewoznik J, Ollila D, Frank J, Krontiras H, Montgomery L, Sarode V, Broadwater G, Esserman L. Sentinel node biopsy performed in the neoadjuvant setting for breast cancer: results from the I-SPY TRIAL (CALGB 150007/150012 & ACRIN 6657). Cancer Research. 69: 202. DOI: 10.1158/0008-5472.Sabcs-202 |
0.401 |
|
| 2009 |
Mao J, Stricker C, Bruner D, Farrar J, Bowman M, Xie S, Wolf J, DeMichele A. Onset and risk factors for aromatase inhibitor-related arthralgia in breast cancer survivors. Cancer Research. 69: 1120. DOI: 10.1158/0008-5472.Sabcs-1120 |
0.526 |
|
| 2009 |
Veer Lv', Das D, DeMichele A, Lenburg M, Singh B, Gray J, Berry D, Hylton N, Esserman L, Investigators I. Neoadjuvant Response in the Context of a Biologically Defined Low or High Risk Tumor Has a Different Clinical Consequence, the I-SPY Trial (CALGB 150007/150012, ACRIN 6657). Cancer Research. 69: 2003-2003. DOI: 10.1158/0008-5472.Sabcs-09-2003 |
0.435 |
|
| 2009 |
Mao J, Gehrman P, Su I, Bruner D, Xie S, Sehamy AE, DeMichele A. Prevalence and Risk Factors for Insomnia in Breast Cancer Survivors Receiving Aromatase Inhibitors. Cancer Research. 69: 1062-1062. DOI: 10.1158/0008-5472.Sabcs-09-1062 |
0.489 |
|
| 2008 |
Matro J, Stankiewicz C, Horn M, Hwang W, Green J, Su I, Velders L, Sherman L, DeMichele A. Clinical and genetic risk factors for bone loss in breast cancer survivors after adjuvant chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 578. PMID 27948692 DOI: 10.1200/Jco.2008.26.15_Suppl.578 |
0.476 |
|
| 2008 |
DeMichele A, Troxel AB, Berlin JA, Weber AL, Bunin GR, Turzo E, Schinnar R, Burgh D, Berlin M, Rubin SC, Rebbeck TR, Strom BL. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4151-9. PMID 18757329 DOI: 10.1200/Jco.2007.14.0921 |
0.491 |
|
| 2008 |
Halbert CH, Weathers B, Esteve R, Audrain-McGovern J, Kumanyika S, DeMichele A, Barg F. Experiences with weight change in African-American breast cancer survivors. The Breast Journal. 14: 182-7. PMID 18282235 DOI: 10.1111/J.1524-4741.2007.00551.X |
0.429 |
|
| 2008 |
Choe R, Konecky SD, Corlu A, Lee K, Durduran T, Zhou C, Czerniecki BJ, Tchou JC, DeMichele A, Rosen MA, Schnall MD, Chance B, Yodh AG. In vivo breast cancer characterization and therapy monitoring using diffuse optical methods based on endogenous optical/exogenous fluorescence contrast Biomedical Optics, Biomed 2008. BSuB1. DOI: 10.1364/Biomed.2008.Bsub1 |
0.329 |
|
| 2008 |
Su H, Sammel M, Velders L, Alton J, Gracia C, DeMichele A. Are cyclophosphamide drug metabolizing enzyme polymorphisms associated with ovarian failure after chemotherapy in young breast cancer patients? Fertility and Sterility. 90: S52. DOI: 10.1016/J.Fertnstert.2008.07.721 |
0.471 |
|
| 2008 |
Su H, Sammel M, Velders L, Alton J, Gracia C, DeMichele A. Chemotherapy related amenorrhea and hormonal measures of ovarian reserve in young breast cancer patients Fertility and Sterility. 90: S273-S274. DOI: 10.1016/J.Fertnstert.2008.07.1167 |
0.522 |
|
| 2007 |
DeMichele A, Gimotty P, Botbyl J, Aplenc R, Colligon T, Foulkes AS, Rebbeck TR. In response to "Drug metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort". Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 5675-7. PMID 18065748 DOI: 10.1200/Jco.2006.10.1485 |
0.427 |
|
| 2007 |
Domchek SM, Recio A, Mick R, Clark CE, Carpenter EL, Fox KR, DeMichele A, Schuchter LM, Leibowitz MS, Wexler MH, Vance BA, Beatty GL, Veloso E, Feldman MD, Vonderheide RH. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Research. 67: 10546-55. PMID 17974999 DOI: 10.1158/0008-5472.Can-07-2765 |
0.391 |
|
| 2007 |
Rebbeck TR, Troxel AB, Norman S, Bunin G, DeMichele A, Schinnar R, Berlin JA, Strom BL. Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk. American Journal of Epidemiology. 166: 1392-9. PMID 17827444 DOI: 10.1093/Aje/Kwm239 |
0.469 |
|
| 2007 |
Rebbeck TR, Troxel AB, Shatalova EG, Blanchard R, Norman S, Bunin G, Demichele A, Schinnar R, Berlin JA, Strom BL. Lack of effect modification between estrogen metabolism genotypes and combined hormone replacement therapy in postmenopausal breast cancer risk. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 1318-20. PMID 17548708 DOI: 10.1158/1055-9965.Epi-07-0084 |
0.474 |
|
| 2007 |
Rebbeck TR, Troxel AB, Walker AH, Panossian S, Gallagher S, Shatalova EG, Blanchard R, Norman S, Bunin G, DeMichele A, Berlin M, Schinnar R, Berlin JA, Strom BL. Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 444-50. PMID 17372239 DOI: 10.1158/1055-9965.Epi-06-0800 |
0.477 |
|
| 2007 |
Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, Weinstein S, Orel SG, Vonderheide R, Coukos G, DeMichele A, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Research. 67: 1842-52. PMID 17293384 DOI: 10.1158/0008-5472.Can-06-4038 |
0.393 |
|
| 2007 |
Rebbeck TR, Troxel AB, Norman S, Bunin GR, DeMichele A, Baumgarten M, Berlin M, Schinnar R, Strom BL. A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. International Journal of Cancer. Journal International Du Cancer. 120: 1523-8. PMID 17205521 DOI: 10.1002/Ijc.22485 |
0.505 |
|
| 2007 |
Gor PP, Gray RJ, Horn M, Rebbeck TR, Gimotty PA, Aplenc R, Pins M, Tallman MS, DeMichele A. Association of polymorphic drug metabolizing enzymes (DME) with outcomes in breast cancer patients treated on the ECOG 2190/Intergroup 0121 (E2190/Int0121) study Journal of Clinical Oncology. 25: 596-596. DOI: 10.1200/Jco.2007.25.18_Suppl.596 |
0.42 |
|
| 2007 |
O'Dwyer PJ, LoRusso P, DeMichele A, Gupta V, Barbi A, Dials H, Chen I, Courtney R, Wilner K, Schwartz GK. A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991 Journal of Clinical Oncology. 25: 3550-3550. DOI: 10.1200/Jco.2007.25.18_Suppl.3550 |
0.314 |
|
| 2007 |
Patel H, Hook K, Kaplan C, Davidson R, DeMichele A, Fox KR, Domchek SM. Utilization of oncotype DX in node-negative, ER-positive breast cancer patients Journal of Clinical Oncology. 25: 11067-11067. DOI: 10.1200/Jco.2007.25.18_Suppl.11067 |
0.426 |
|
| 2007 |
Su I, Alton J, Sherman L, Stankiewicz C, Ratcliffe S, DeMichele A. Relationships between clinical and biochemical predictors of chemotherapy-related amenorrhea in premenopausal adjuvant breast cancer patients Journal of Clinical Oncology. 25: 11011-11011. DOI: 10.1200/Jco.2007.25.18_Suppl.11011 |
0.559 |
|
| 2006 |
Strom BL, Schinnar R, Weber AL, Bunin G, Berlin JA, Baumgarten M, DeMichele A, Rubin SC, Berlin M, Troxel AB, Rebbeck TR. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. American Journal of Epidemiology. 164: 775-86. PMID 16997897 DOI: 10.1093/Aje/Kwj316 |
0.401 |
|
| 2006 |
Rebbeck TR, Troxel AB, Wang Y, Walker AH, Panossian S, Gallagher S, Shatalova EG, Blanchard R, Bunin G, DeMichele A, Rubin SC, Baumgarten M, Berlin M, Schinnar R, Berlin JA, et al. Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. Journal of the National Cancer Institute. 98: 1311-20. PMID 16985250 DOI: 10.1093/Jnci/Djj360 |
0.401 |
|
| 2006 |
Harris EE, Hwang WT, Lee EA, Cengel KA, Feldman MD, Demichele A, Kao G, Solin LJ. The impact of HER-2 status on local recurrence in women with stage I-II breast cancer treated with breast-conserving therapy. The Breast Journal. 12: 431-6. PMID 16958961 DOI: 10.1111/J.1075-122X.2006.00297.X |
0.52 |
|
| 2006 |
Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, Begg CB, Caporaso N, Chanock S, DeMichele A, Figg WD, Gospodarowicz MK, Hall EJ, Hisada M, Inskip P, et al. Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. Journal of the National Cancer Institute. 98: 15-25. PMID 16391368 DOI: 10.1093/Jnci/Djj001 |
0.436 |
|
| 2005 |
Domchek SM, Fox KR, Recio A, Schuchter LM, Davidson R, Demichele A, Feldman MD, Vonderheide RH. Telomerase vaccination of metastatic breast cancer patients induces antigen-specific tumor infiltrating lymphocytes and tumor necrosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2505. PMID 27945956 DOI: 10.1200/Jco.2005.23.16_Suppl.2505 |
0.435 |
|
| 2005 |
Smith K, Wray L, Klein-Cabral M, Schuchter L, Fox K, Glick J, DeMichele A. Ethnic disparities in adjuvant chemotherapy for breast cancer are not caused by excess toxicity in black patients. Clinical Breast Cancer. 6: 260-6; discussion 26. PMID 16137438 DOI: 10.3816/Cbc.2005.N.029 |
0.522 |
|
| 2005 |
DeMichele A, Aplenc R, Botbyl J, Colligan T, Wray L, Klein-Cabral M, Foulkes A, Gimotty P, Glick J, Weber B, Stadtmauer E, Rebbeck TR. Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5552-9. PMID 16110016 DOI: 10.1200/Jco.2005.06.208 |
0.439 |
|
| 2005 |
Choe R, Corlu A, Lee K, Durduran T, Konecky SD, Grosicka-Koptyra M, Arridge SR, Czerniecki BJ, Fraker DL, DeMichele A, Chance B, Rosen MA, Yodh AG. Diffuse optical tomography of breast cancer during neoadjuvant chemotherapy: a case study with comparison to MRI. Medical Physics. 32: 1128-39. PMID 15895597 DOI: 10.1118/1.1869612 |
0.427 |
|
| 2005 |
Demichele A, Troxel A, Weber A, Berlin J, Bunin G, Turzo E, Burgh D, Schinnar R, Rubin S, Rebbeck T, Strom B. Effect of raloxifene on endometrial cancer risk in a population-based, case-control study Journal of Clinical Oncology. 23: 5001-5001. DOI: 10.1200/Jco.2005.23.16_Suppl.5001 |
0.501 |
|
| 2004 |
Purev E, Cai D, Miller E, Swoboda R, Mayer T, Klein-Szanto A, Marincola FM, Mick R, Otvos L, Wunner W, Birebent B, Somasundaram R, Wikstrand CJ, Bigner D, DeMichele A, et al. Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R). Journal of Immunology (Baltimore, Md. : 1950). 173: 6472-80. PMID 15528389 DOI: 10.4049/Jimmunol.173.10.6472 |
0.41 |
|
| 2004 |
Palmer SC, Kagee A, Coyne JC, DeMichele A. Experience of Trauma, Distress, and Posttraumatic Stress Disorder among Breast Cancer Patients Psychosomatic Medicine. 66: 258-264. PMID 15039512 DOI: 10.1097/01.Psy.0000116755.71033.10 |
0.461 |
|
| 2004 |
Coyne JC, Palmer SC, Shapiro PJ, Thompson R, DeMichele A. Distress, psychiatric morbidity, and prescriptions for psychotropic medication in a breast cancer waiting room sample. General Hospital Psychiatry. 26: 121-8. PMID 15038929 DOI: 10.1016/J.Genhosppsych.2003.08.012 |
0.399 |
|
| 2004 |
Matthews G, Alton J, Jacobs LA, Palmer S, Meadows AT, Demichele A. Predictors of quality of life among breast cancer survivors Journal of Clinical Oncology. 22: 8128-8128. DOI: 10.1200/Jco.2004.22.90140.8128 |
0.509 |
|
| 2004 |
Harris ER, Hwang W, Lee EA, Cengel KA, DeMichele A, Solin LJ. The impact of Her2/neu status on local recurrence in women with stage I-II breast cancer treated with breast conservation therapy International Journal of Radiation Oncology Biology Physics. 60. DOI: 10.1016/J.Ijrobp.2004.06.036 |
0.51 |
|
| 2004 |
Stein S, DeMichele A, Domchek S, Fox K. Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer overexpressing HER2/neu Clinical Breast Cancer. 4. |
0.467 |
|
| 2003 |
DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M, Athanasiadis G, Colligan T, Stadtmauer E, Weber B. Interleukin-6 - 174G→C Polymorphism Is Associated with Improved Outcome in High-Risk Breast Cancer Cancer Research. 63: 8051-8056. PMID 14633738 |
0.312 |
|
| 2003 |
Rock E, DeMichele A. Nutritional Approaches to Late Toxicities of Adjuvant Chemotherapy in Breast Cancer Survivors Journal of Nutrition. 133. PMID 14608115 DOI: 10.1093/Jn/133.11.3785S |
0.496 |
|
| 2003 |
DeMichele A, Putt M, Zhang Y, Glick JH, Norman S. Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients. Cancer. 97: 2150-9. PMID 12712466 DOI: 10.1002/Cncr.11338 |
0.31 |
|
| 2003 |
Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 999-1006. PMID 12637463 DOI: 10.1200/Jco.2003.05.068 |
0.457 |
|
| 1997 |
DeMichele A, Weber BL. Recent advances in breast cancer biology Current Opinion in Oncology. 9: 499-504. PMID 9370069 DOI: 10.1097/00001622-199711000-00002 |
0.454 |
|
| Show low-probability matches. |